Document Name: role of Crodafos CES (Cetearyl Alcohol (and) Cetearyl Phosphate) in Protective Cream4
Document link: https://patents.google.com/patent/US20190365642A1/en



US20190365642A1 - Method and Formulation for Improving Roflumilast Skin Penetration Lag Time 
      - Google Patents


























US20190365642A1 - Method and Formulation for Improving Roflumilast Skin Penetration Lag Time 
      - Google Patents
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time 
     

Download PDF
Info

Publication number
US20190365642A1



US20190365642A1
US16/426,492
US201916426492A
US2019365642A1
US 20190365642 A1
US20190365642 A1
US 20190365642A1
 
 
 
US 201916426492 A
US201916426492 A
US 201916426492A
US 2019365642 A1
US2019365642 A1
US 2019365642A1
Authority
US
United States
Prior art keywords
roflumilast
phosphate
pharmaceutical composition
skin
composition
Prior art date
2018-06-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending


Application number
US16/426,492
Inventor
David W. Osborne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

    Arcutis Biotherapeutics Inc
  
Original Assignee
Arcutis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2018-06-04
Filing date
2019-05-30
Publication date
2019-12-05


Priority claimed from US201862680203P
external-priority


2019-05-30
Application filed by Arcutis Inc
filed
Critical
Arcutis Inc


2019-05-30
Priority to US16/426,492
priority
Critical
patent/US20190365642A1/en


2019-12-05
Publication of US20190365642A1
publication
Critical
patent/US20190365642A1/en


2021-12-22
Assigned to SLR INVESTMENT CORP., AS AGENT
reassignment
SLR INVESTMENT CORP., AS AGENT
SECURITY INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors: ARCUTIS BIOTHERAPEUTICS, INC.


Status
Pending
legal-status
Critical
Current

Links



USPTO



USPTO PatentCenter



USPTO Assignment



Espacenet



Global Dossier



Discuss




MNDBXUUTURYVHR-UHFFFAOYSA-N
Roflumilast
Chemical compound


FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1
MNDBXUUTURYVHR-UHFFFAOYSA-N
0.000
title
claims
abstract
description
206


229960002586
Roflumilast
Drugs




0.000
title
claims
abstract
description
204


239000000203
mixture
Substances




0.000
title
claims
abstract
description
188


230000035832
Lag time
Effects




0.000
title
claims
abstract
description
78


230000035648
Lag-time
Effects




0.000
title
claims
abstract
description
78


230000037335
skin penetration
Effects




0.000
title
claims
abstract
description
36


238000009472
formulation
Methods




0.000
title
description
30


239000010452
phosphate
Substances




0.000
claims
abstract
description
76


NBIIXXVUZAFLBC-UHFFFAOYSA-K
[O-]P([O-])([O-])=O
Chemical compound


[O-]P([O-])([O-])=O
NBIIXXVUZAFLBC-UHFFFAOYSA-K
0.000
claims
abstract
description
56


239000003995
emulsifying agent
Substances




0.000
claims
abstract
description
38


RNPXCFINMKSQPQ-UHFFFAOYSA-N
dicetyl hydrogen phosphate
Chemical compound


CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC
RNPXCFINMKSQPQ-UHFFFAOYSA-N
0.000
claims
abstract
description
28


229940093541
dicetylphosphate
Drugs




0.000
claims
abstract
description
28


229940081733
cetearyl alcohol
Drugs




0.000
claims
abstract
description
20


UBHWBODXJBSFLH-UHFFFAOYSA-N
hexadecan-1-ol;octadecan-1-ol
Chemical compound


CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO
UBHWBODXJBSFLH-UHFFFAOYSA-N
0.000
claims
abstract
description
20


XXJWXESWEXIICW-UHFFFAOYSA-N
2-(2-Ethoxyethoxy)ethanol
Chemical compound


CCOCCOCCO
XXJWXESWEXIICW-UHFFFAOYSA-N
0.000
claims
description
71


-1
phosphate ester
Chemical class




0.000
claims
description
58


239000008194
pharmaceutical composition
Substances




0.000
claims
description
32


239000004094
surface-active agent
Substances




0.000
claims
description
24


229940075557
diethylene glycol monoethyl ether
Drugs




0.000
claims
description
18


230000002209
hydrophobic
Effects




0.000
claims
description
16


239000002904
solvent
Substances




0.000
claims
description
16


239000002674
ointment
Substances




0.000
claims
description
14


IAKHMKGGTNLKSZ-INIZCTEOSA-N
Colchicine
Chemical compound


C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC
IAKHMKGGTNLKSZ-INIZCTEOSA-N
0.000
claims
description
12


239000004909
Moisturizer
Substances




0.000
claims
description
12


GHMLBKRAJCXXBS-UHFFFAOYSA-N
Resorcinol
Chemical compound


OC1=CC=CC(O)=C1
GHMLBKRAJCXXBS-UHFFFAOYSA-N
0.000
claims
description
12


YGSDEFSMJLZEOE-UHFFFAOYSA-N
Salicylic acid
Chemical compound


OC(=O)C1=CC=CC=C1O
YGSDEFSMJLZEOE-UHFFFAOYSA-N
0.000
claims
description
12


239000003795
chemical substances by application
Substances




0.000
claims
description
12


230000001333
moisturizer
Effects




0.000
claims
description
12


WYWHKKSPHMUBEB-UHFFFAOYSA-N
tioguanine
Chemical compound


N1C(N)=NC(=S)C2=C1N=CN2
WYWHKKSPHMUBEB-UHFFFAOYSA-N
0.000
claims
description
12


XSQUKJJJFZCRTK-UHFFFAOYSA-N
urea
Chemical compound


NC(N)=O
XSQUKJJJFZCRTK-UHFFFAOYSA-N
0.000
claims
description
12


NUZWLKWWNNJHPT-UHFFFAOYSA-N
Dithranol
Chemical compound


C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O
NUZWLKWWNNJHPT-UHFFFAOYSA-N
0.000
claims
description
10


201000008937
atopic dermatitis
Diseases




0.000
claims
description
10


229960002311
dithranol
Drugs




0.000
claims
description
10


229940075495
isopropyl palmitate
Drugs




0.000
claims
description
10


239000002562
thickening agent
Substances




0.000
claims
description
10


XUGNVMKQXJXZCD-UHFFFAOYSA-N
Isopropyl palmitate
Chemical compound


CCCCCCCCCCCCCCCC(=O)OC(C)C
XUGNVMKQXJXZCD-UHFFFAOYSA-N
0.000
claims
description
8


229920000642
polymer
Polymers




0.000
claims
description
8


OQANPHBRHBJGNZ-FYJGNVAPSA-N
(3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid
Chemical compound


C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1
OQANPHBRHBJGNZ-FYJGNVAPSA-N
0.000
claims
description
6


PMATZTZNYRCHOR-CGLBZJNRSA-N
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17
Chemical compound


CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O
PMATZTZNYRCHOR-CGLBZJNRSA-N
0.000
claims
description
6


RTGDFNSFWBGLEC-SYZQJQIISA-N
2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
Chemical compound


COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
RTGDFNSFWBGLEC-SYZQJQIISA-N
0.000
claims
description
6


GHASVSINZRGABV-UHFFFAOYSA-N
5-flurouricil
Chemical compound


FC1=CNC(=O)NC1=O
GHASVSINZRGABV-UHFFFAOYSA-N
0.000
claims
description
6


MJZJYWCQPMNPRM-UHFFFAOYSA-N
6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE
Chemical compound


CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl
MJZJYWCQPMNPRM-UHFFFAOYSA-N
0.000
claims
description
6


108010007562
Adalimumab
Proteins




0.000
claims
description
6


RZOBLYBZQXQGFY-UHFFFAOYSA-N
Ammonium lactate
Chemical compound


[NH4+].CC(O)C([O-])=O
RZOBLYBZQXQGFY-UHFFFAOYSA-N
0.000
claims
description
6


239000004251
Ammonium lactate
Substances




0.000
claims
description
6


229940025660
Anthralin
Drugs




0.000
claims
description
6


229940064005
Antibiotic throat preparations
Drugs




0.000
claims
description
6


229940083879
Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
Drugs




0.000
claims
description
6


229940042052
Antibiotics for systemic use
Drugs




0.000
claims
description
6


229940042786
Antitubercular Antibiotics
Drugs




0.000
claims
description
6


229960002170
Azathioprine
Drugs




0.000
claims
description
6


229940108066
Coal Tar
Drugs




0.000
claims
description
6


229940064701
Corticosteroid nasal preparations for topical use
Drugs




0.000
claims
description
6


229960001334
Corticosteroids
Drugs




0.000
claims
description
6


102400000739
Corticotropin
Human genes




0.000
claims
description
6


101800000414
Corticotropin
Proteins




0.000
claims
description
6


229940119017
Cyclosporine
Drugs




0.000
claims
description
6


108010036949
Cyclosporine
Proteins




0.000
claims
description
6


229960002949
Fluorouracil
Drugs




0.000
claims
description
6


229940093922
Gynecological Antibiotics
Drugs




0.000
claims
description
6


108010053490
Infliximab
Proteins




0.000
claims
description
6


FBOZXECLQNJBKD-ZDUSSCGKSA-N
L-methotrexate
Chemical compound


C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1
FBOZXECLQNJBKD-ZDUSSCGKSA-N
0.000
claims
description
6


229960004469
Methoxsalen
Drugs




0.000
claims
description
6


229960001940
Sulfasalazine
Drugs




0.000
claims
description
6


229960001967
Tacrolimus
Drugs




0.000
claims
description
6


QJJXYPPXXYFBGM-LFZNUXCKSA-N
Tacrolimus
Chemical compound


C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1
QJJXYPPXXYFBGM-LFZNUXCKSA-N
0.000
claims
description
6


229960005454
Thioguanine
Drugs




0.000
claims
description
6


229940024982
Topical Antifungal Antibiotics
Drugs




0.000
claims
description
6


229940045136
Urea
Drugs




0.000
claims
description
6


108010077389
Ustekinumab
Proteins




0.000
claims
description
6


229940046008
Vitamin D
Drugs




0.000
claims
description
6


229930003316
Vitamin D
Natural products




0.000
claims
description
6


QXKHYNVANLEOEG-UHFFFAOYSA-N
XANTHOTOXIN
Chemical compound


C1=CC(=O)OC2=C1C=C1C=COC1=C2OC
QXKHYNVANLEOEG-UHFFFAOYSA-N
0.000
claims
description
6


OGQICQVSFDPSEI-UHFFFAOYSA-N
Zorac
Chemical compound


N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1
OGQICQVSFDPSEI-UHFFFAOYSA-N
0.000
claims
description
6


229960005339
acitretin
Drugs




0.000
claims
description
6


229960002964
adalimumab
Drugs




0.000
claims
description
6


IHUNBGSDBOWDMA-AQFIFDHZSA-N
all-trans-acitretin
Chemical compound


COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C
IHUNBGSDBOWDMA-AQFIFDHZSA-N
0.000
claims
description
6


229940059265
ammonium lactate
Drugs




0.000
claims
description
6


235000019286
ammonium lactate
Nutrition




0.000
claims
description
6


239000003242
anti bacterial agent
Substances




0.000
claims
description
6


LMEKQMALGUDUQG-UHFFFAOYSA-N
azathioprine
Chemical compound


CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2
LMEKQMALGUDUQG-UHFFFAOYSA-N
0.000
claims
description
6


230000003115
biocidal
Effects




0.000
claims
description
6


239000004202
carbamide
Substances




0.000
claims
description
6


229960000539
carbamide
Drugs




0.000
claims
description
6


229960001265
ciclosporin
Drugs




0.000
claims
description
6


239000011280
coal tar
Substances




0.000
claims
description
6


229960001338
colchicine
Drugs




0.000
claims
description
6


239000003246
corticosteroid
Substances




0.000
claims
description
6


IDLFZVILOHSSID-OVLDLUHVSA-N
corticotropin
Chemical compound


C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1
IDLFZVILOHSSID-OVLDLUHVSA-N
0.000
claims
description
6


229960000258
corticotropin
Drugs




0.000
claims
description
6


150000002237
fumaric acid derivatives
Chemical class




0.000
claims
description
6


229960001330
hydroxycarbamide
Drugs




0.000
claims
description
6


VSNHCAURESNICA-UHFFFAOYSA-N
hydroxyurea
Chemical compound


NC(=O)NO
VSNHCAURESNICA-UHFFFAOYSA-N
0.000
claims
description
6


229940027318
hydroxyurea
Drugs




0.000
claims
description
6


229960000598
infliximab
Drugs




0.000
claims
description
6


229940079866
intestinal antibiotics
Drugs




0.000
claims
description
6


229960000485
methotrexate
Drugs




0.000
claims
description
6


229960004866
mycophenolate mofetil
Drugs




0.000
claims
description
6


239000007764
o/w emulsion
Substances




0.000
claims
description
6


229940005935
ophthalmologic Antibiotics
Drugs




0.000
claims
description
6


229960001755
resorcinol
Drugs




0.000
claims
description
6


229960004889
salicylic acid
Drugs




0.000
claims
description
6


229960000565
tazarotene
Drugs




0.000
claims
description
6


229940083878
topical for treatment of hemorrhoids and anal fissures Corticosteroids
Drugs




0.000
claims
description
6


229960003824
ustekinumab
Drugs




0.000
claims
description
6


235000019166
vitamin D
Nutrition




0.000
claims
description
6


239000011710
vitamin D
Substances




0.000
claims
description
6


150000003710
vitamin D derivatives
Chemical class




0.000
claims
description
6


206010012438
Dermatitis atopic
Diseases




0.000
claims
description
4


239000002518
antifoaming agent
Substances




0.000
claims
description
4


239000003963
antioxidant agent
Substances




0.000
claims
description
4


UIIMBOGNXHQVGW-UHFFFAOYSA-M
buffer
Substances


[Na+].OC([O-])=O
UIIMBOGNXHQVGW-UHFFFAOYSA-M
0.000
claims
description
4


239000000975
dye
Substances




0.000
claims
description
4


239000003205
fragrance
Substances




0.000
claims
description
4


239000000049
pigment
Substances




0.000
claims
description
4


230000002335
preservative
Effects




0.000
claims
description
4


239000003755
preservative agent
Substances




0.000
claims
description
4


239000003352
sequestering agent
Substances




0.000
claims
description
4


239000003381
stabilizer
Substances




0.000
claims
description
4


230000003078
antioxidant
Effects




0.000
claims
2


230000004968
inflammatory condition
Effects




0.000
claims
2


239000003961
penetration enhancing agent
Substances




0.000
claims
2


201000010099
disease
Diseases




0.000
abstract
description
18


230000036912
Bioavailability
Effects




0.000
abstract
description
10


230000035514
bioavailability
Effects




0.000
abstract
description
10


230000003247
decreasing
Effects




0.000
abstract
description
4


210000003491
Skin
Anatomy




0.000
description
126


239000006071
cream
Substances




0.000
description
86


XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Substances


O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
66


239000003814
drug
Substances




0.000
description
54


HEMHJVSKTPXQMS-UHFFFAOYSA-M
sodium hydroxide
Chemical compound


[OH-].[Na+]
HEMHJVSKTPXQMS-UHFFFAOYSA-M
0.000
description
54


229940079593
drugs
Drugs




0.000
description
50


230000000699
topical
Effects




0.000
description
48


239000000839
emulsion
Substances




0.000
description
36


239000012071
phase
Substances




0.000
description
34


LXCFILQKKLGQFO-UHFFFAOYSA-N
Methylparaben
Chemical compound


COC(=O)C1=CC=C(O)C=C1
LXCFILQKKLGQFO-UHFFFAOYSA-N
0.000
description
28


239000000047
product
Substances




0.000
description
28


230000004941
influx
Effects




0.000
description
26


150000001875
compounds
Chemical class




0.000
description
22


210000002381
Plasma
Anatomy




0.000
description
20


239000004480
active ingredient
Substances




0.000
description
20


229940051250
hexylene glycol
Drugs




0.000
description
20


230000000275
pharmacokinetic
Effects




0.000
description
20


SVTBMSDMJJWYQN-UHFFFAOYSA-N
2-Methyl-2,4-pentanediol
Chemical compound


CC(O)CC(C)(C)O
SVTBMSDMJJWYQN-UHFFFAOYSA-N
0.000
description
18


210000004369
Blood
Anatomy




0.000
description
18


239000008280
blood
Substances




0.000
description
18


LFQSCWFLJHTTHZ-UHFFFAOYSA-N
ethanol
Chemical compound


CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
description
18


229940025703
Topical Product
Drugs




0.000
description
16


239000008387
emulsifying waxe
Substances




0.000
description
16


239000000499
gel
Substances




0.000
description
16


239000004292
methyl p-hydroxybenzoate
Substances




0.000
description
16


235000010270
methyl p-hydroxybenzoate
Nutrition




0.000
description
16


229960002216
methylparaben
Drugs




0.000
description
16


229940066842
Petrolatum
Drugs




0.000
description
14


239000004264
Petrolatum
Substances




0.000
description
14


208000006641
Skin Disease
Diseases




0.000
description
14


241000282898
Sus scrofa
Species




0.000
description
14


239000003921
oil
Substances




0.000
description
14


235000019271
petrolatum
Nutrition




0.000
description
14


239000000825
pharmaceutical preparation
Substances




0.000
description
14


239000004405
propyl p-hydroxybenzoate
Substances




0.000
description
14


235000010232
propyl p-hydroxybenzoate
Nutrition




0.000
description
14


229960003415
propylparaben
Drugs




0.000
description
14


210000000434
stratum corneum
Anatomy




0.000
description
14


QELSKZZBTMNZEB-UHFFFAOYSA-N
Propylparaben
Chemical compound


CCCOC(=O)C1=CC=C(O)C=C1
QELSKZZBTMNZEB-UHFFFAOYSA-N
0.000
description
12


229940100611
Topical Cream
Drugs




0.000
description
12


239000008186
active pharmaceutical agent
Substances




0.000
description
12


230000002757
inflammatory
Effects




0.000
description
12


235000019198
oils
Nutrition




0.000
description
12


NIXOWILDQLNWCW-UHFFFAOYSA-N
acrylic acid
Chemical compound


OC(=O)C=C
NIXOWILDQLNWCW-UHFFFAOYSA-N
0.000
description
10


239000008346
aqueous phase
Substances




0.000
description
10


230000001186
cumulative
Effects




0.000
description
10


RTZKZFJDLAIYFH-UHFFFAOYSA-N
diethyl ether
Chemical compound


CCOCC
RTZKZFJDLAIYFH-UHFFFAOYSA-N
0.000
description
10


238000009792
diffusion process
Methods




0.000
description
10


239000006260
foam
Substances




0.000
description
10


239000008213
purified water
Substances




0.000
description
10


ICIDSZQHPUZUHC-UHFFFAOYSA-N
2-octadecoxyethanol
Chemical compound


CCCCCCCCCCCCCCCCCCOCCO
ICIDSZQHPUZUHC-UHFFFAOYSA-N
0.000
description
8


BXWNKGSJHAJOGX-UHFFFAOYSA-N
Cetyl alcohol
Chemical compound


CCCCCCCCCCCCCCCCO
BXWNKGSJHAJOGX-UHFFFAOYSA-N
0.000
description
8


241000124008
Mammalia
Species




0.000
description
8


241001465754
Metazoa
Species




0.000
description
8


229920002675
Polyoxyl
Polymers




0.000
description
8


229940082500
cetostearyl alcohol
Drugs




0.000
description
8


239000002552
dosage form
Substances




0.000
description
8


239000011521
glass
Substances




0.000
description
8


PEDCQBHIVMGVHV-UHFFFAOYSA-N
glycerine
Chemical compound


OCC(O)CO
PEDCQBHIVMGVHV-UHFFFAOYSA-N
0.000
description
8


238000000338
in vitro
Methods




0.000
description
8


KFZMGEQAYNKOFK-UHFFFAOYSA-N
iso-propanol
Chemical compound


CC(C)O
KFZMGEQAYNKOFK-UHFFFAOYSA-N
0.000
description
8


238000004519
manufacturing process
Methods




0.000
description
8


239000000463
material
Substances




0.000
description
8


238000000034
method
Methods




0.000
description
8


101710031992
pRL90232
Proteins




0.000
description
8


101710035540
plaa2
Proteins




0.000
description
8


230000036470
plasma concentration
Effects




0.000
description
8


229920001888
polyacrylic acid
Polymers




0.000
description
8


ZLMJMSJWJFRBEC-UHFFFAOYSA-N
potassium
Chemical compound


[K]
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
0.000
description
8


239000011591
potassium
Substances




0.000
description
8


229910052700
potassium
Inorganic materials




0.000
description
8


201000004681
psoriasis
Diseases




0.000
description
8


238000011002
quantification
Methods




0.000
description
8


150000003839
salts
Chemical class




0.000
description
8


238000005070
sampling
Methods




0.000
description
8


239000011780
sodium chloride
Substances




0.000
description
8


229910001220
stainless steel
Inorganic materials




0.000
description
8


239000010935
stainless steel
Substances




0.000
description
8


NUWGGCCCYHIPEG-UHFFFAOYSA-N
2-(2-hydroxyethoxy)ethanol;phosphoric acid
Chemical compound


OP(O)(O)=O.OCCOCCO
NUWGGCCCYHIPEG-UHFFFAOYSA-N
0.000
description
6


229960001631
Carbomer
Drugs




0.000
description
6


210000004207
Dermis
Anatomy




0.000
description
6


210000002615
Epidermis
Anatomy




0.000
description
6


210000000981
Epithelium
Anatomy




0.000
description
6


210000004209
Hair
Anatomy




0.000
description
6


NNPPMTNAJDCUHE-UHFFFAOYSA-N
Isobutane
Chemical compound


CC(C)C
NNPPMTNAJDCUHE-UHFFFAOYSA-N
0.000
description
6


239000004166
Lanolin
Substances




0.000
description
6


229940039717
Lanolin
Drugs




0.000
description
6


GLDOVTGHNKAZLK-UHFFFAOYSA-N
Stearyl alcohol
Chemical compound


CCCCCCCCCCCCCCCCCCO
GLDOVTGHNKAZLK-UHFFFAOYSA-N
0.000
description
6


241000282887
Suidae
Species




0.000
description
6


230000035507
absorption
Effects




0.000
description
6


238000010521
absorption reaction
Methods




0.000
description
6


XEKOWRVHYACXOJ-UHFFFAOYSA-N
acetic acid ethyl ester
Chemical compound


CCOC(C)=O
XEKOWRVHYACXOJ-UHFFFAOYSA-N
0.000
description
6


CSCPPACGZOOCGX-UHFFFAOYSA-N
acetone
Chemical compound


CC(C)=O
CSCPPACGZOOCGX-UHFFFAOYSA-N
0.000
description
6


230000000172
allergic
Effects




0.000
description
6


WVDDGKGOMKODPV-UHFFFAOYSA-N
benzyl alcohol
Chemical compound


OCC1=CC=CC=C1
WVDDGKGOMKODPV-UHFFFAOYSA-N
0.000
description
6


238000004638
bioanalytical method
Methods




0.000
description
6


IJDNQMDRQITEOD-UHFFFAOYSA-N
butane
Chemical compound


CCCC
IJDNQMDRQITEOD-UHFFFAOYSA-N
0.000
description
6


239000004359
castor oil
Substances




0.000
description
6


235000019438
castor oil
Nutrition




0.000
description
6


210000004027
cells
Anatomy




0.000
description
6


229960000541
cetyl alcohol
Drugs




0.000
description
6


229920001577
copolymer
Polymers




0.000
description
6


LCGLNKUTAGEVQW-UHFFFAOYSA-N
dimethyl ether
Chemical compound


COC
LCGLNKUTAGEVQW-UHFFFAOYSA-N
0.000
description
6


230000002500
effect on skin
Effects




0.000
description
6


239000003623
enhancer
Substances




0.000
description
6


230000002708
enhancing
Effects




0.000
description
6


239000012052
hydrophilic carrier
Substances




0.000
description
6


230000002401
inhibitory effect
Effects




0.000
description
6


239000001282
iso-butane
Substances




0.000
description
6


235000013847
iso-butane
Nutrition




0.000
description
6


235000019388
lanolin
Nutrition




0.000
description
6


238000002156
mixing
Methods




0.000
description
6


239000012188
paraffin wax
Substances




0.000
description
6


238000005192
partition
Methods




0.000
description
6


230000035515
penetration
Effects




0.000
description
6


239000012466
permeate
Substances




0.000
description
6


229920001223
polyethylene glycol
Polymers




0.000
description
6


230000002062
proliferating
Effects




0.000
description
6


239000003380
propellant
Substances




0.000
description
6


239000007921
spray
Substances




0.000
description
6


QIQXTHQIDYTFRH-UHFFFAOYSA-M
stearate
Chemical compound


CCCCCCCCCCCCCCCCCC([O-])=O
QIQXTHQIDYTFRH-UHFFFAOYSA-M
0.000
description
6


238000003756
stirring
Methods




0.000
description
6


239000000725
suspension
Substances




0.000
description
6


210000001519
tissues
Anatomy




0.000
description
6


GMRQFYUYWCNGIN-NKMMMXOESA-N
(1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol
Chemical compound


C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
GMRQFYUYWCNGIN-NKMMMXOESA-N
0.000
description
4


CTXGTHVAWRBISV-UHFFFAOYSA-N
2-hydroxyethyl dodecanoate
Chemical compound


CCCCCCCCCCCC(=O)OCCO
CTXGTHVAWRBISV-UHFFFAOYSA-N
0.000
description
4


RMTFNDVZYPHUEF-XZBKPIIZSA-N
3-O-methyl-D-glucose
Chemical compound


O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO
RMTFNDVZYPHUEF-XZBKPIIZSA-N
0.000
description
4


210000001015
Abdomen
Anatomy




0.000
description
4


FJXOGVLKCZQRDN-PHCHRAKRSA-N
Alclometasone
Chemical compound


C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O
FJXOGVLKCZQRDN-PHCHRAKRSA-N
0.000
description
4


229960003099
Amcinonide
Drugs




0.000
description
4


ILKJAFIWWBXGDU-MOGDOJJUSA-N
Amcinonide
Chemical compound


O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1
ILKJAFIWWBXGDU-MOGDOJJUSA-N
0.000
description
4


UREBDLICKHMUKA-DVTGEIKXSA-N
Betamethasone
Chemical compound


C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O
UREBDLICKHMUKA-DVTGEIKXSA-N
0.000
description
4


229960005084
CALCITRIOL
Drugs




0.000
description
4


229940073639
CETEARETH-6
Drugs




0.000
description
4


LWQQLNNNIPYSNX-UROSTWAQSA-N
Calcipotriol
Chemical compound


C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1
LWQQLNNNIPYSNX-UROSTWAQSA-N
0.000
description
4


229940117583
Cocamine
Drugs




0.000
description
4


JYGXADMDTFJGBT-VWUMJDOOSA-N
Cortisol
Chemical compound


O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1
JYGXADMDTFJGBT-VWUMJDOOSA-N
0.000
description
4


WBGKWQHBNHJJPZ-LECWWXJVSA-N
Desonide
Chemical compound


C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O
WBGKWQHBNHJJPZ-LECWWXJVSA-N
0.000
description
4


229960002593
Desoximetasone
Drugs




0.000
description
4


229960003957
Dexamethasone
Drugs




0.000
description
4


UREBDLICKHMUKA-CXSFZGCWSA-N
Dexamethasone
Chemical compound


C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O
UREBDLICKHMUKA-CXSFZGCWSA-N
0.000
description
4


230000036826
Excretion
Effects




0.000
description
4


POPFMWWJOGLOIF-XWCQMRHXSA-N
Fludroxycortide
Chemical compound


C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O
POPFMWWJOGLOIF-XWCQMRHXSA-N
0.000
description
4


UUOUOERPONYGOS-CLCRDYEYSA-N
Fluocinolone
Chemical compound


O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1
UUOUOERPONYGOS-CLCRDYEYSA-N
0.000
description
4


WJOHZNCJWYWUJD-IUGZLZTKSA-N
Fluocinonide
Chemical compound


C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O
WJOHZNCJWYWUJD-IUGZLZTKSA-N
0.000
description
4


229940013644
Flurandrenolide
Drugs




0.000
description
4


RFVNOJDQRGSOEL-UHFFFAOYSA-N
Glycol stearate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCCO
RFVNOJDQRGSOEL-UHFFFAOYSA-N
0.000
description
4


VEXZGXHMUGYJMC-UHFFFAOYSA-N
HCl
Chemical compound


Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-N
0.000
description
4


MUQNGPZZQDCDFT-JNQJZLCISA-N
Halcinonide
Chemical compound


C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O
MUQNGPZZQDCDFT-JNQJZLCISA-N
0.000
description
4


241000282412
Homo
Species




0.000
description
4


AOMUHOFOVNGZAN-UHFFFAOYSA-N
Lauroyl diethanolamide
Chemical compound


CCCCCCCCCCCC(=O)N(CCO)CCO
AOMUHOFOVNGZAN-UHFFFAOYSA-N
0.000
description
4


230000036740
Metabolism
Effects




0.000
description
4


VHRSUDSXCMQTMA-PJHHCJLFSA-N
Methylprednisolone
Chemical compound


C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21
VHRSUDSXCMQTMA-PJHHCJLFSA-N
0.000
description
4


229960001664
Mometasone
Drugs




0.000
description
4


229940049964
Oleate
Drugs




0.000
description
4


ZQPPMHVWECSIRJ-KTKRTIGZSA-N
Oleic acid
Chemical compound


CCCCCCCC\C=C/CCCCCCCC(O)=O
ZQPPMHVWECSIRJ-KTKRTIGZSA-N
0.000
description
4


229920003171
Poly (ethylene oxide)
Polymers




0.000
description
4


229920002565
Polyethylene Glycol 400
Polymers




0.000
description
4


FNPXMHRZILFCKX-KAJVQRHHSA-N
Prednicarbate
Chemical compound


C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O
FNPXMHRZILFCKX-KAJVQRHHSA-N
0.000
description
4


XOFYZVNMUHMLCC-ZPOLXVRWSA-N
Prednisone
Chemical compound


O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N
0.000
description
4


206010040882
Skin lesion
Diseases




0.000
description
4


229940052907
Telazol
Drugs




0.000
description
4


ZFXYFBGIUFBOJW-UHFFFAOYSA-N
Theophylline
Chemical compound


O=C1N(C)C(=O)N(C)C2=C1NC=N2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N
0.000
description
4


GFNANZIMVAIWHM-OBYCQNJPSA-N
Triamcinolone
Chemical compound


O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1
GFNANZIMVAIWHM-OBYCQNJPSA-N
0.000
description
4


LEHFPXVYPMWYQD-XHIJKXOTSA-N
Ulobetasol
Chemical compound


C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]2(C)C[C@@H]1O
LEHFPXVYPMWYQD-XHIJKXOTSA-N
0.000
description
4


210000003462
Veins
Anatomy




0.000
description
4


MEESPVWIOBCLJW-KTKRTIGZSA-L
[(Z)-octadec-9-enyl] phosphate
Chemical compound


CCCCCCCC\C=C/CCCCCCCCOP([O-])([O-])=O
MEESPVWIOBCLJW-KTKRTIGZSA-L
0.000
description
4


125000000129
anionic group
Chemical group




0.000
description
4


229960002537
betamethasone
Drugs




0.000
description
4


238000004166
bioassay
Methods




0.000
description
4


HOWJQLVNDUGZBI-UHFFFAOYSA-N
butane;propane
Chemical compound


CCC.CCCC
HOWJQLVNDUGZBI-UHFFFAOYSA-N
0.000
description
4


229960004649
calcipotriene
Drugs




0.000
description
4


235000020964
calcitriol
Nutrition




0.000
description
4


239000011612
calcitriol
Substances




0.000
description
4


125000002091
cationic group
Chemical group




0.000
description
4


235000019994
cava
Nutrition




0.000
description
4


230000001684
chronic
Effects




0.000
description
4


229960002842
clobetasol
Drugs




0.000
description
4


FCSHDIVRCWTZOX-DVTGEIKXSA-N
clobetasol
Chemical compound


C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O
FCSHDIVRCWTZOX-DVTGEIKXSA-N
0.000
description
4


231100000223
dermal penetration
Toxicity




0.000
description
4


229960003662
desonide
Drugs




0.000
description
4


VWVSBHGCDBMOOT-IIEHVVJPSA-N
desoximetasone
Chemical compound


C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O
VWVSBHGCDBMOOT-IIEHVVJPSA-N
0.000
description
4


238000001514
detection method
Methods




0.000
description
4


235000014113
dietary fatty acids
Nutrition




0.000
description
4


229960004154
diflorasone
Drugs




0.000
description
4


WXURHACBFYSXBI-XHIJKXOTSA-N
diflorasone
Chemical compound


C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O
WXURHACBFYSXBI-XHIJKXOTSA-N
0.000
description
4


QXNVGIXVLWOKEQ-UHFFFAOYSA-N
disodium
Chemical compound


[Na][Na]
QXNVGIXVLWOKEQ-UHFFFAOYSA-N
0.000
description
4


YVIGPQSYEAOLAD-UHFFFAOYSA-L
disodium;dodecyl phosphate
Chemical compound


[Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O
YVIGPQSYEAOLAD-UHFFFAOYSA-L
0.000
description
4


230000035510
distribution
Effects




0.000
description
4


239000003937
drug carrier
Substances




0.000
description
4


230000029142
excretion
Effects




0.000
description
4


238000002474
experimental method
Methods




0.000
description
4


239000000194
fatty acid
Substances




0.000
description
4


229960004511
fludroxycortide
Drugs




0.000
description
4


229940043075
fluocinolone
Drugs




0.000
description
4


229960000785
fluocinonide
Drugs




0.000
description
4


125000005456
glyceride group
Chemical group




0.000
description
4


235000011187
glycerol
Nutrition




0.000
description
4


229960002383
halcinonide
Drugs




0.000
description
4


229940115747
halobetasol
Drugs




0.000
description
4


229960000890
hydrocortisone
Drugs




0.000
description
4


239000003112
inhibitor
Substances




0.000
description
4


125000001449
isopropyl group
Chemical group


[H]C([H])([H])C([H])(*)C([H])([H])[H]

0.000
description
4


239000007788
liquid
Substances




0.000
description
4


239000006210
lotion
Substances




0.000
description
4


230000004060
metabolic process
Effects




0.000
description
4


230000035786
metabolism
Effects




0.000
description
4


229960004584
methylprednisolone
Drugs




0.000
description
4


239000002480
mineral oil
Substances




0.000
description
4


235000010446
mineral oil
Nutrition




0.000
description
4


QLIIKPVHVRXHRI-CXSFZGCWSA-N
mometasone
Chemical compound


C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O
QLIIKPVHVRXHRI-CXSFZGCWSA-N
0.000
description
4


210000004877
mucosa
Anatomy




0.000
description
4


LRHPLDYGYMQRHN-UHFFFAOYSA-N
n-butanol
Chemical compound


CCCCO
LRHPLDYGYMQRHN-UHFFFAOYSA-N
0.000
description
4


229920005615
natural polymer
Polymers




0.000
description
4


HGASFNYMVGEKTF-UHFFFAOYSA-N
octan-1-ol;hydrate
Chemical compound


O.CCCCCCCCO
HGASFNYMVGEKTF-UHFFFAOYSA-N
0.000
description
4


ZQPPMHVWECSIRJ-KTKRTIGZSA-M
oleate
Chemical compound


CCCCCCCC\C=C/CCCCCCCC([O-])=O
ZQPPMHVWECSIRJ-KTKRTIGZSA-M
0.000
description
4


239000006072
paste
Substances




0.000
description
4


230000036231
pharmacokinetics
Effects




0.000
description
4


229960002794
prednicarbate
Drugs




0.000
description
4


229960004618
prednisone
Drugs




0.000
description
4


DNIAPMSPPWPWGF-UHFFFAOYSA-N
propylene glycol
Chemical compound


CC(O)CO
DNIAPMSPPWPWGF-UHFFFAOYSA-N
0.000
description
4


230000001185
psoriatic
Effects




0.000
description
4


VBICKXHEKHSIBG-UHFFFAOYSA-N
rac-1-monostearoylglycerol
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO
VBICKXHEKHSIBG-UHFFFAOYSA-N
0.000
description
4


230000037384
skin absorption
Effects




0.000
description
4


231100000274
skin absorption
Toxicity




0.000
description
4


231100000444
skin lesion
Toxicity




0.000
description
4


239000008223
sterile water
Substances




0.000
description
4


QAOWNCQODCNURD-UHFFFAOYSA-L
sulfate
Chemical compound


[O-]S([O-])(=O)=O
QAOWNCQODCNURD-UHFFFAOYSA-L
0.000
description
4


229920001059
synthetic polymer
Polymers




0.000
description
4


230000001839
systemic circulation
Effects




0.000
description
4


230000001225
therapeutic
Effects




0.000
description
4


QAXBVGVYDCAVLV-UHFFFAOYSA-N
tiletamine
Chemical compound


C=1C=CSC=1C1(NCC)CCCCC1=O
QAXBVGVYDCAVLV-UHFFFAOYSA-N
0.000
description
4


239000012049
topical pharmaceutical composition
Substances




0.000
description
4


231100000419
toxicity
Toxicity




0.000
description
4


230000001988
toxicity
Effects




0.000
description
4


229960005294
triamcinolone
Drugs




0.000
description
4


239000007762
w/o emulsion
Substances




0.000
description
4


NOOLISFMXDJSKH-UTLUCORTSA-N
(+)-Neomenthol
Chemical compound


CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O
NOOLISFMXDJSKH-UTLUCORTSA-N
0.000
description
2


XMGQYMWWDOXHJM-UHFFFAOYSA-N
(+-)-(RS)-limonene
Chemical compound


CC(=C)C1CCC(C)=CC1
XMGQYMWWDOXHJM-UHFFFAOYSA-N
0.000
description
2


LNAZSHAWQACDHT-XIYTZBAFSA-N
(2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane
Chemical compound


CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC
LNAZSHAWQACDHT-XIYTZBAFSA-N
0.000
description
2


IQXJCCZJOIKIAD-UHFFFAOYSA-N
1-(2-methoxyethoxy)hexadecane
Chemical compound


CCCCCCCCCCCCCCCCOCCOC
IQXJCCZJOIKIAD-UHFFFAOYSA-N
0.000
description
2


HLZKNKRTKFSKGZ-UHFFFAOYSA-N
1-Tetradecanol
Chemical compound


CCCCCCCCCCCCCCO
HLZKNKRTKFSKGZ-UHFFFAOYSA-N
0.000
description
2


MLHOXUWWKVQEJB-UHFFFAOYSA-N
1-acetyloxypropan-2-yl acetate
Chemical compound


CC(=O)OC(C)COC(C)=O
MLHOXUWWKVQEJB-UHFFFAOYSA-N
0.000
description
2


JLPULHDHAOZNQI-ZTIMHPMXSA-N
1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine
Chemical compound


CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC
JLPULHDHAOZNQI-ZTIMHPMXSA-N
0.000
description
2


QHZLMUACJMDIAE-UHFFFAOYSA-N
1-monopalmitoylglycerol
Chemical compound


CCCCCCCCCCCCCCCC(=O)OCC(O)CO
QHZLMUACJMDIAE-UHFFFAOYSA-N
0.000
description
2


OVYMWJFNQQOJBU-UHFFFAOYSA-N
1-octanoyloxypropan-2-yl octanoate
Chemical compound


CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC
OVYMWJFNQQOJBU-UHFFFAOYSA-N
0.000
description
2


RZRNAYUHWVFMIP-KTKRTIGZSA-N
1-oleoylglycerol
Chemical compound


CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO
RZRNAYUHWVFMIP-KTKRTIGZSA-N
0.000
description
2


WNWHHMBRJJOGFJ-UHFFFAOYSA-N
16-methylheptadecan-1-ol
Chemical compound


CC(C)CCCCCCCCCCCCCCCO
WNWHHMBRJJOGFJ-UHFFFAOYSA-N
0.000
description
2


WXZMFSXDPGVJKK-UHFFFAOYSA-N
2,2-bis(hydroxymethyl)propane-1,3-diol
Chemical compound


OCC(CO)(CO)CO
WXZMFSXDPGVJKK-UHFFFAOYSA-N
0.000
description
2


ZFFMLCVRJBZUDZ-UHFFFAOYSA-N
2,3-Dimethylbutane
Chemical group


CC(C)C(C)C
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N
0.000
description
2


OEZPKXDBWNXBRE-UHFFFAOYSA-N
2,3-bis(2-hydroxyethoxy)propyl dodecanoate
Chemical compound


CCCCCCCCCCCC(=O)OCC(OCCO)COCCO
OEZPKXDBWNXBRE-UHFFFAOYSA-N
0.000
description
2


AZLWQVJVINEILY-UHFFFAOYSA-N
2-(2-dodecoxyethoxy)ethanol
Chemical compound


CCCCCCCCCCCCOCCOCCO
AZLWQVJVINEILY-UHFFFAOYSA-N
0.000
description
2


PWVUXRBUUYZMKM-UHFFFAOYSA-N
2-(2-hydroxyethoxy)ethyl octadecanoate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCCOCCO
PWVUXRBUUYZMKM-UHFFFAOYSA-N
0.000
description
2


VOFRZBBLONRUHY-KVVVOXFISA-N
2-(2-hydroxyethylamino)ethanol;2-[2-[2-[(Z)-octadec-9-enoxy]ethoxy]ethoxy]ethyl dihydrogen phosphate
Chemical compound


OCCNCCO.CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOP(O)(O)=O
VOFRZBBLONRUHY-KVVVOXFISA-N
0.000
description
2


KWVPFECTOKLOBL-KTKRTIGZSA-N
2-[(Z)-octadec-9-enoxy]ethanol
Chemical compound


CCCCCCCC\C=C/CCCCCCCCOCCO
KWVPFECTOKLOBL-KTKRTIGZSA-N
0.000
description
2


MGYUQZIGNZFZJS-KTKRTIGZSA-N
2-[2-[(Z)-octadec-9-enoxy]ethoxy]ethanol
Chemical compound


CCCCCCCC\C=C/CCCCCCCCOCCOCCO
MGYUQZIGNZFZJS-KTKRTIGZSA-N
0.000
description
2


MQFYRUGXOJAUQK-UHFFFAOYSA-N
2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC
MQFYRUGXOJAUQK-UHFFFAOYSA-N
0.000
description
2


PWQNOLAKMCLNJI-KTKRTIGZSA-N
2-[2-[2-[(Z)-octadec-9-enoxy]ethoxy]ethoxy]ethyl dihydrogen phosphate
Chemical compound


CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOP(O)(O)=O
PWQNOLAKMCLNJI-KTKRTIGZSA-N
0.000
description
2


NPYXBHZQVNRAOF-UHFFFAOYSA-N
2-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]ethanol
Chemical compound


C1C=C2CC(OCCO)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2
NPYXBHZQVNRAOF-UHFFFAOYSA-N
0.000
description
2


ZVUNTIMPQCQCAQ-UHFFFAOYSA-N
2-dodecanoyloxyethyl dodecanoate
Chemical compound


CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC
ZVUNTIMPQCQCAQ-UHFFFAOYSA-N
0.000
description
2


IISGCGDBIBXFOD-UHFFFAOYSA-N
2-dodecoxy-2-oxoethanesulfonic acid;sodium
Chemical compound


[Na].[Na].CCCCCCCCCCCCOC(=O)CS(O)(=O)=O
IISGCGDBIBXFOD-UHFFFAOYSA-N
0.000
description
2


AJKXDPSHWRTFOZ-UHFFFAOYSA-N
2-ethylhexane-1,6-diol
Chemical compound


CCC(CO)CCCCO
AJKXDPSHWRTFOZ-UHFFFAOYSA-N
0.000
description
2


GTRGFUCVDQMYKO-UHFFFAOYSA-N
2-hydroxyethyl 16-methylheptadecanoate
Chemical compound


CC(C)CCCCCCCCCCCCCCC(=O)OCCO
GTRGFUCVDQMYKO-UHFFFAOYSA-N
0.000
description
2


FKOKUHFZNIUSLW-UHFFFAOYSA-N
2-hydroxypropyl octadecanoate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCC(C)O
FKOKUHFZNIUSLW-UHFFFAOYSA-N
0.000
description
2


WLAMNBDJUVNPJU-UHFFFAOYSA-N
2-methylbutyric acid
Chemical compound


CCC(C)C(O)=O
WLAMNBDJUVNPJU-UHFFFAOYSA-N
0.000
description
2


IPHYGCMVLYWKLM-UHFFFAOYSA-N
2-octadec-9-enoxyethanol;phosphoric acid
Chemical compound


OP(O)(O)=O.CCCCCCCCC=CCCCCCCCCOCCO
IPHYGCMVLYWKLM-UHFFFAOYSA-N
0.000
description
2


LEACJMVNYZDSKR-UHFFFAOYSA-N
2-octyldodecan-1-ol
Chemical compound


CCCCCCCCCCC(CO)CCCCCCCC
LEACJMVNYZDSKR-UHFFFAOYSA-N
0.000
description
2


YWBLIYFXWVRDAA-MDZDMXLPSA-N
3-hydroxypropyl (E)-octadec-9-enoate
Chemical compound


CCCCCCCC\C=C\CCCCCCCC(=O)OCCCO
YWBLIYFXWVRDAA-MDZDMXLPSA-N
0.000
description
2


CWSZBVAUYPTXTG-UHFFFAOYSA-N
5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol
Chemical compound


O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1
CWSZBVAUYPTXTG-UHFFFAOYSA-N
0.000
description
2


229940063953
AMMONIUM LAURYL SULFATE
Drugs




0.000
description
2


206010000496
Acne
Diseases




0.000
description
2


208000004631
Alopecia Areata
Diseases




0.000
description
2


BTBJBAZGXNKLQC-UHFFFAOYSA-N
Ammonium lauryl sulfate
Chemical compound


[NH4+].CCCCCCCCCCCCOS([O-])(=O)=O
BTBJBAZGXNKLQC-UHFFFAOYSA-N
0.000
description
2


229940006211
Anticholinergic mydriatics and cycloplegics
Drugs




0.000
description
2


229940065524
Anticholinergics inhalants for obstructive airway diseases
Drugs




0.000
description
2


229960000686
Benzalkonium Chloride
Drugs




0.000
description
2


230000036868
Blood Concentration
Effects




0.000
description
2


230000035639
Blood Levels
Effects




0.000
description
2


229940073642
CETEARETH-30
Drugs




0.000
description
2


229940098691
COCO MONOETHANOLAMIDE
Drugs




0.000
description
2


229940048300
COCO-CAPRYLATE
Drugs




0.000
description
2


229920002134
Carboxymethyl cellulose
Polymers




0.000
description
2


229940113118
Carrageenan
Drugs




0.000
description
2


210000000170
Cell Membrane
Anatomy




0.000
description
2


210000003169
Central Nervous System
Anatomy




0.000
description
2


229940093528
Cetearyl Ethylhexanoate
Drugs




0.000
description
2


229940056318
Ceteth-20
Drugs




0.000
description
2


MYSWGUAQZAJSOK-UHFFFAOYSA-N
Ciprofloxacin
Chemical compound


C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1
MYSWGUAQZAJSOK-UHFFFAOYSA-N
0.000
description
2


208000004921
Cutaneous Lupus Erythematosus
Diseases




0.000
description
2


229940066254
DIMETHICONE PEG-7 PHOSPHATE
Drugs




0.000
description
2


229940079886
DISODIUM LAURYL SULFOSUCCINATE
Drugs




0.000
description
2


229940080249
DISODIUM OLEAMIDO MEA-SULFOSUCCINATE
Drugs




0.000
description
2


GHVNFZFCNZKVNT-UHFFFAOYSA-N
Decanoic acid
Chemical compound


CCCCCCCCCC(O)=O
GHVNFZFCNZKVNT-UHFFFAOYSA-N
0.000
description
2


ZDQWESQEGGJUCH-UHFFFAOYSA-N
Diisopropyl adipate
Chemical compound


CC(C)OC(=O)CCCCC(=O)OC(C)C
ZDQWESQEGGJUCH-UHFFFAOYSA-N
0.000
description
2


APSBXTVYXVQYAB-UHFFFAOYSA-M
Dioctyl sodium sulfosuccinate
Chemical compound


[Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC
APSBXTVYXVQYAB-UHFFFAOYSA-M
0.000
description
2


208000006926
Discoid Lupus Erythematosus
Diseases




0.000
description
2


229940047642
Disodium Cocoamphodiacetate
Drugs




0.000
description
2


239000003109
Disodium ethylene diamine tetraacetate
Substances




0.000
description
2


NOPFSRXAKWQILS-UHFFFAOYSA-N
Docosanol
Chemical compound


CCCCCCCCCCCCCCCCCCCCCCO
NOPFSRXAKWQILS-UHFFFAOYSA-N
0.000
description
2


229960000878
Docusate Sodium
Drugs




0.000
description
2


208000005679
Eczema
Diseases




0.000
description
2


ULGZDMOVFRHVEP-RWJQBGPGSA-N
Erythromycin
Chemical compound


O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1
ULGZDMOVFRHVEP-RWJQBGPGSA-N
0.000
description
2


210000001723
Extracellular Space
Anatomy




0.000
description
2


229940074052
GLYCERYL ISOSTEARATE
Drugs




0.000
description
2


229940074046
GLYCERYL LAURATE
Drugs




0.000
description
2


229940096898
GLYCERYL PALMITATE
Drugs




0.000
description
2


229940100608
GLYCOL DISTEARATE
Drugs




0.000
description
2


CEAZRRDELHUEMR-URQXQFDESA-N
Gentamicin
Chemical compound


O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N
CEAZRRDELHUEMR-URQXQFDESA-N
0.000
description
2


229940100242
Glycol Stearate
Drugs




0.000
description
2


FPVVYTCTZKCSOJ-UHFFFAOYSA-N
Glycol distearate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC
FPVVYTCTZKCSOJ-UHFFFAOYSA-N
0.000
description
2


229920002907
Guar gum
Polymers




0.000
description
2


230000036499
Half live
Effects




0.000
description
2


UQEAIHBTYFGYIE-UHFFFAOYSA-N
Hexamethyldisiloxane
Chemical compound


C[Si](C)(C)O[Si](C)(C)C
UQEAIHBTYFGYIE-UHFFFAOYSA-N
0.000
description
2


239000004354
Hydroxyethyl cellulose
Substances




0.000
description
2


229920000663
Hydroxyethyl cellulose
Polymers




0.000
description
2


229920002153
Hydroxypropyl cellulose
Polymers




0.000
description
2


229940093629
ISOPROPYL ISOSTEARATE
Drugs




0.000
description
2


206010061218
Inflammation
Diseases




0.000
description
2


229940119837
Isopropyl Alcohol
Drugs




0.000
description
2


AXISYYRBXTVTFY-UHFFFAOYSA-N
Isopropyl myristate
Chemical compound


CCCCCCCCCCCCCC(=O)OC(C)C
AXISYYRBXTVTFY-UHFFFAOYSA-N
0.000
description
2


229940100491
LAURETH-2
Drugs




0.000
description
2


229960004873
LEVOMENTHOL
Drugs




0.000
description
2


229920002884
Laureth 4
Polymers




0.000
description
2


229940100556
Laureth-23
Drugs




0.000
description
2


229940067606
Lecithin
Drugs




0.000
description
2


229940059904
Light Mineral Oil
Drugs




0.000
description
2


229940100485
METHYL GLUCETH-10
Drugs




0.000
description
2


229940044591
METHYL GLUCOSE DIOLEATE
Drugs




0.000
description
2


229940057917
Medium chain triglycerides
Drugs




0.000
description
2


210000004379
Membranes
Anatomy




0.000
description
2


229940041616
Menthol
Drugs




0.000
description
2


230000035633
Metabolized
Effects




0.000
description
2


229960000282
Metronidazole
Drugs




0.000
description
2


229940042472
Mineral Oil
Drugs




0.000
description
2


ARIWANIATODDMH-UHFFFAOYSA-N
Monolaurin
Chemical compound


CCCCCCCCCCCC(=O)OCC(O)CO
ARIWANIATODDMH-UHFFFAOYSA-N
0.000
description
2


210000002200
Mouth Mucosa
Anatomy




0.000
description
2


150000001204
N-oxides
Chemical class




0.000
description
2


210000000282
Nails
Anatomy




0.000
description
2


229940046947
OLETH-10 PHOSPHATE
Drugs




0.000
description
2


229940099570
OLETH-2
Drugs




0.000
description
2


229940095127
OLETH-20
Drugs




0.000
description
2


239000005642
Oleic acid
Substances




0.000
description
2


ALSTYHKOOCGGFT-KTKRTIGZSA-N
Oleyl alcohol
Chemical compound


CCCCCCCC\C=C/CCCCCCCCO
ALSTYHKOOCGGFT-KTKRTIGZSA-N
0.000
description
2


XAPRFLSJBSXESP-UHFFFAOYSA-N
Oxycinchophen
Chemical compound


N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1
XAPRFLSJBSXESP-UHFFFAOYSA-N
0.000
description
2


229940100460
PEG-100 Stearate
Drugs




0.000
description
2


229940094334
PEG-25 PROPYLENE GLYCOL STEARATE
Drugs




0.000
description
2


229940032066
PEG-4 DILAURATE
Drugs




0.000
description
2


229940032041
PEG-8 LAURATE
Drugs




0.000
description
2


229940093448
POLOXAMER 124
Drugs




0.000
description
2


229940085692
POLOXAMER 181
Drugs




0.000
description
2


229940099511
POLYSORBATE 65
Drugs




0.000
description
2


229940033623
POTASSIUM LAURYL PHOSPHATE
Drugs




0.000
description
2


235000019483
Peanut oil
Nutrition




0.000
description
2


229940100462
Pegoxol 7 Stearate
Drugs




0.000
description
2


229920002507
Poloxamer 124
Polymers




0.000
description
2


229920002508
Poloxamer 181
Polymers




0.000
description
2


229920002509
Poloxamer 182
Polymers




0.000
description
2


229940093426
Poloxamer 182
Drugs




0.000
description
2


229940044519
Poloxamer 188
Drugs




0.000
description
2


229920002511
Poloxamer 237
Polymers




0.000
description
2


229940044476
Poloxamer 407
Drugs




0.000
description
2


239000002202
Polyethylene glycol
Substances




0.000
description
2


229920002669
Polyoxyl 20 Cetostearyl Ether
Polymers




0.000
description
2


229920002690
Polyoxyl 40 HydrogenatedCastorOil
Polymers




0.000
description
2


229920002701
Polyoxyl 40 Stearate
Polymers




0.000
description
2


229940099429
Polyoxyl 40 Stearate
Drugs




0.000
description
2


229920001213
Polysorbate 20
Polymers




0.000
description
2


229940068977
Polysorbate 20
Drugs




0.000
description
2


229920001219
Polysorbate 40
Polymers




0.000
description
2


229920001214
Polysorbate 60
Polymers




0.000
description
2


229920002642
Polysorbate 65
Polymers




0.000
description
2


229940068968
Polysorbate 80
Drugs




0.000
description
2


229940116423
Propylene glycol diacetate
Drugs




0.000
description
2


208000003251
Pruritus
Diseases




0.000
description
2


229940048842
SODIUM XYLENESULFONATE
Drugs




0.000
description
2


229940098760
STEARETH-2
Drugs




0.000
description
2


229940100459
STEARETH-20
Drugs




0.000
description
2


229940100458
STEARETH-21
Drugs




0.000
description
2


210000004761
Scalp
Anatomy




0.000
description
2


206010039580
Scar
Diseases




0.000
description
2


JNYAEWCLZODPBN-CTQIIAAMSA-N
Sorbitan
Chemical compound


OCC(O)C1OCC(O)[C@@H]1O
JNYAEWCLZODPBN-CTQIIAAMSA-N
0.000
description
2


HVUMOYIDDBPOLL-XWVZOOPGSA-N
Sorbitan monostearate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O
HVUMOYIDDBPOLL-XWVZOOPGSA-N
0.000
description
2


QIQXTHQIDYTFRH-UHFFFAOYSA-N
Stearic acid
Chemical compound


CCCCCCCCCCCCCCCCCC(O)=O
QIQXTHQIDYTFRH-UHFFFAOYSA-N
0.000
description
2


LSNNMFCWUKXFEE-UHFFFAOYSA-L
Sulphite
Chemical compound


[O-]S([O-])=O
LSNNMFCWUKXFEE-UHFFFAOYSA-L
0.000
description
2


206010042496
Sunburn
Diseases




0.000
description
2


229960000278
Theophylline
Drugs




0.000
description
2


229940072029
Trilaureth-4 Phosphate
Drugs




0.000
description
2


NWGKJDSIEKMTRX-AAZCQSIUSA-N
[(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate
Chemical compound


CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O
NWGKJDSIEKMTRX-AAZCQSIUSA-N
0.000
description
2


NWGKJDSIEKMTRX-BFWOXRRGSA-N
[(2R)-2-[(3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate
Chemical compound


CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O
NWGKJDSIEKMTRX-BFWOXRRGSA-N
0.000
description
2


IYFATESGLOUGBX-NDUCAMMLSA-N
[2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate
Chemical compound


CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O
IYFATESGLOUGBX-NDUCAMMLSA-N
0.000
description
2


ILYTUKNTXBTWLC-QXMHVHEDSA-N
[ethoxy(hydroxy)phosphoryl] (Z)-octadec-9-enoate
Chemical compound


CCCCCCCC\C=C/CCCCCCCC(=O)OP(O)(=O)OCC
ILYTUKNTXBTWLC-QXMHVHEDSA-N
0.000
description
2


230000001154
acute
Effects




0.000
description
2


239000000443
aerosol
Substances




0.000
description
2


239000000556
agonist
Substances




0.000
description
2


150000001298
alcohols
Chemical class




0.000
description
2


125000002877
alkyl aryl group
Chemical group




0.000
description
2


230000002009
allergen
Effects




0.000
description
2


229910052782
aluminium
Inorganic materials




0.000
description
2


XAGFODPZIPBFFR-UHFFFAOYSA-N
aluminum
Chemical compound


[Al]
XAGFODPZIPBFFR-UHFFFAOYSA-N
0.000
description
2


230000001078
anti-cholinergic
Effects




0.000
description
2


230000000111
anti-oxidant
Effects




0.000
description
2


239000002249
anxiolytic agent
Substances




0.000
description
2


230000002917
arthritic
Effects




0.000
description
2


230000004888
barrier function
Effects




0.000
description
2


235000019445
benzyl alcohol
Nutrition




0.000
description
2


230000015572
biosynthetic process
Effects




0.000
description
2


239000001273
butane
Substances




0.000
description
2


ULBTUVJTXULMLP-UHFFFAOYSA-N
butyl octadecanoate
Chemical compound


CCCCCCCCCCCCCCCCCC(=O)OCCCC
ULBTUVJTXULMLP-UHFFFAOYSA-N
0.000
description
2


PUPZLCDOIYMWBV-UHFFFAOYSA-N
butylene glycol
Chemical compound


CC(O)CCO
PUPZLCDOIYMWBV-UHFFFAOYSA-N
0.000
description
2


GHVNFZFCNZKVNT-UHFFFAOYSA-M
caprate
Chemical compound


CCCCCCCCCC([O-])=O
GHVNFZFCNZKVNT-UHFFFAOYSA-M
0.000
description
2


229940075508
carbomer homopolymer type b
Drugs




0.000
description
2


229940049638
carbomer homopolymer type c
Drugs




0.000
description
2


235000010948
carboxy methyl cellulose
Nutrition




0.000
description
2


239000001768
carboxy methyl cellulose
Substances




0.000
description
2


239000008112
carboxymethyl-cellulose
Substances




0.000
description
2


229940096529
carboxypolymethylene
Drugs




0.000
description
2


235000010418
carrageenan
Nutrition




0.000
description
2


239000000679
carrageenan
Substances




0.000
description
2


229920001525
carrageenan
Polymers




0.000
description
2


239000000969
carrier
Substances




0.000
description
2


229940073669
ceteareth 20
Drugs




0.000
description
2


229940073638
ceteareth-15
Drugs




0.000
description
2


229940081620
ceteth-2
Drugs




0.000
description
2


229940115464
ceteth-23
Drugs




0.000
description
2


229940074979
cetyl palmitate
Drugs




0.000
description
2


239000000812
cholinergic antagonist
Substances




0.000
description
2


229960003405
ciprofloxacin
Drugs




0.000
description
2


230000004087
circulation
Effects




0.000
description
2


229940110456
cocoa butter
Drugs




0.000
description
2


235000019868
cocoa butter
Nutrition




0.000
description
2


229940071160
cocoate
Drugs




0.000
description
2


239000003240
coconut oil
Substances




0.000
description
2


235000019864
coconut oil
Nutrition




0.000
description
2


238000001816
cooling
Methods




0.000
description
2


239000002537
cosmetic
Substances




0.000
description
2


229940086555
cyclomethicone
Drugs




0.000
description
2


LXVAEMFXVFEJNV-UHFFFAOYSA-N
decanedioic acid;hexanedioic acid
Chemical compound


OC(=O)CCCCC(O)=O.OC(=O)CCCCCCCCC(O)=O
LXVAEMFXVFEJNV-UHFFFAOYSA-N
0.000
description
2


230000001419
dependent
Effects




0.000
description
2


201000004624
dermatitis
Diseases




0.000
description
2


ONKUXPIBXRRIDU-UHFFFAOYSA-N
diethyl decanedioate
Chemical compound


CCOC(=O)CCCCCCCCC(=O)OCC
ONKUXPIBXRRIDU-UHFFFAOYSA-N
0.000
description
2


125000004177
diethyl group
Chemical group


[H]C([H])([H])C([H])([H])*

0.000
description
2


125000004786
difluoromethoxy group
Chemical group


[H]C(F)(F)O*

0.000
description
2


229940031578
diisopropyl adipate
Drugs




0.000
description
2


229940008099
dimethicone
Drugs




0.000
description
2


239000004205
dimethyl polysiloxane
Substances




0.000
description
2


235000013870
dimethyl polysiloxane
Nutrition




0.000
description
2


229960001760
dimethyl sulfoxide
Drugs




0.000
description
2


IAZDPXIOMUYVGZ-UHFFFAOYSA-N
dimethylsulphoxide
Chemical compound


CS(C)=O
IAZDPXIOMUYVGZ-UHFFFAOYSA-N
0.000
description
2


235000019329
dioctyl sodium sulphosuccinate
Nutrition




0.000
description
2


GWTCIAGIKURVBJ-UHFFFAOYSA-L
dipotassium;dodecyl phosphate
Chemical compound


[K+].[K+].CCCCCCCCCCCCOP([O-])([O-])=O
GWTCIAGIKURVBJ-UHFFFAOYSA-L
0.000
description
2


235000019301
disodium ethylene diamine tetraacetate
Nutrition




0.000
description
2


229940079868
disodium laureth sulfosuccinate
Drugs




0.000
description
2


ZGTMUACCHSMWAC-UHFFFAOYSA-L
disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate
Chemical compound


[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O
ZGTMUACCHSMWAC-UHFFFAOYSA-L
0.000
description
2


YGAXLGGEEQLLKV-UHFFFAOYSA-L
disodium;4-dodecoxy-4-oxo-2-sulfonatobutanoate
Chemical compound


[Na+].[Na+].CCCCCCCCCCCCOC(=O)CC(C([O-])=O)S([O-])(=O)=O
YGAXLGGEEQLLKV-UHFFFAOYSA-L
0.000
description
2


KHIQYZGEUSTKSB-UHFFFAOYSA-L
disodium;4-dodecoxy-4-oxo-3-sulfobutanoate
Chemical compound


[Na+].[Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O.CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O
KHIQYZGEUSTKSB-UHFFFAOYSA-L
0.000
description
2


238000006073
displacement reaction
Methods




0.000
description
2


238000004090
dissolution
Methods




0.000
description
2


CYFHLEMYBPQRGN-UHFFFAOYSA-M
ditetradecyl phosphate
Chemical compound


CCCCCCCCCCCCCCOP([O-])(=O)OCCCCCCCCCCCCCC
CYFHLEMYBPQRGN-UHFFFAOYSA-M
0.000
description
2


229960000735
docosanol
Drugs




0.000
description
2


TVACALAUIQMRDF-UHFFFAOYSA-L
dodecyl phosphate
Chemical compound


CCCCCCCCCCCCOP([O-])([O-])=O
TVACALAUIQMRDF-UHFFFAOYSA-L
0.000
description
2


229950008597
drug INN
Drugs




0.000
description
2


230000036267
drug metabolism
Effects




0.000
description
2


231100001003
eczema
Toxicity




0.000
description
2


229940009662
edetate
Drugs




0.000
description
2


KCXVZYZYPLLWCC-UHFFFAOYSA-N
edta
Chemical compound


OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O
KCXVZYZYPLLWCC-UHFFFAOYSA-N
0.000
description
2


230000000694
effects
Effects




0.000
description
2


239000003974
emollient agent
Substances




0.000
description
2


229960003276
erythromycin
Drugs




0.000
description
2


229940093499
ethyl acetate
Drugs




0.000
description
2


150000004665
fatty acids
Chemical class




0.000
description
2


239000000945
filler
Substances




0.000
description
2


230000004907
flux
Effects




0.000
description
2


230000002496
gastric
Effects




0.000
description
2


229960002518
gentamicin
Drugs




0.000
description
2


229940075507
glyceryl monostearate
Drugs




0.000
description
2


229940075529
glyceryl stearate
Drugs




0.000
description
2


LYCAIKOWRPUZTN-UHFFFAOYSA-N
glycol
Chemical compound


OCCO
LYCAIKOWRPUZTN-UHFFFAOYSA-N
0.000
description
2


239000000665
guar gum
Substances




0.000
description
2


235000010417
guar gum
Nutrition




0.000
description
2


229960002154
guar gum
Drugs




0.000
description
2


230000036074
healthy skin
Effects




0.000
description
2


ZUVCYFMOHFTGDM-UHFFFAOYSA-L
hexadecyl phosphate
Chemical compound


CCCCCCCCCCCCCCCCOP([O-])([O-])=O
ZUVCYFMOHFTGDM-UHFFFAOYSA-L
0.000
description
2


IIRDTKBZINWQAW-UHFFFAOYSA-N
hexaethylene glycol
Chemical class


OCCOCCOCCOCCOCCOCCO
IIRDTKBZINWQAW-UHFFFAOYSA-N
0.000
description
2


125000004836
hexamethylene group
Chemical group


[H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1]

0.000
description
2


ZWVMLYRJXORSEP-UHFFFAOYSA-N
hexane-1,2,6-triol
Chemical compound


OCCCCC(O)CO
ZWVMLYRJXORSEP-UHFFFAOYSA-N
0.000
description
2


239000012456
homogeneous solution
Substances




0.000
description
2


229920001519
homopolymer
Polymers




0.000
description
2


239000003906
humectant
Substances




0.000
description
2


230000036571
hydration
Effects




0.000
description
2


238000006703
hydration reaction
Methods




0.000
description
2


239000008311
hydrophilic ointment
Substances




0.000
description
2


235000019447
hydroxyethyl cellulose
Nutrition




0.000
description
2


235000010977
hydroxypropyl cellulose
Nutrition




0.000
description
2


239000001863
hydroxypropyl cellulose
Substances




0.000
description
2


230000001969
hypertrophic
Effects




0.000
description
2


230000004054
inflammatory process
Effects




0.000
description
2


239000004615
ingredient
Substances




0.000
description
2


229910052500
inorganic mineral
Inorganic materials




0.000
description
2


238000001990
intravenous administration
Methods




0.000
description
2


229960004592
isopropanol
Drugs




0.000
description
2


229940074928
isopropyl myristate
Drugs




0.000
description
2


229940061515
laureth-4
Drugs




0.000
description
2


235000010445
lecithin
Nutrition




0.000
description
2


239000000787
lecithin
Substances




0.000
description
2


150000002617
leukotrienes
Chemical class




0.000
description
2


229940087305
limonene
Drugs




0.000
description
2


229930007650
limonene
Natural products




0.000
description
2


235000001510
limonene
Nutrition




0.000
description
2


150000002632
lipids
Chemical class




0.000
description
2


238000001294
liquid chromatography-tandem mass spectrometry
Methods




0.000
description
2


238000005259
measurement
Methods




0.000
description
2


239000012528
membrane
Substances




0.000
description
2


229920000609
methyl cellulose
Polymers




0.000
description
2


229940031722
methyl gluceth-20
Drugs




0.000
description
2


239000001923
methylcellulose
Substances




0.000
description
2


235000010981
methylcellulose
Nutrition




0.000
description
2


VAOCPAMSLUNLGC-UHFFFAOYSA-N
metronidazole
Chemical compound


CC1=NC=C([N+]([O-])=O)N1CCO
VAOCPAMSLUNLGC-UHFFFAOYSA-N
0.000
description
2


239000004200
microcrystalline wax
Substances




0.000
description
2


235000019808
microcrystalline wax
Nutrition




0.000
description
2


239000011707
mineral
Substances




0.000
description
2


230000004048
modification
Effects




0.000
description
2


238000006011
modification reaction
Methods




0.000
description
2


239000001788
mono and diglycerides of fatty acids
Substances




0.000
description
2


229940043348
myristyl alcohol
Drugs




0.000
description
2


SECXISVLQFMRJM-UHFFFAOYSA-N
n-methylpyrrolidone
Chemical compound


CN1CCCC1=O
SECXISVLQFMRJM-UHFFFAOYSA-N
0.000
description
2


201000009053
neurodermatitis
Diseases




0.000
description
2


PREFCHVVKZWHMM-UHFFFAOYSA-N
octan-3-yl 2-hydroxyoctadecanoate
Chemical compound


CCCCCCCCCCCCCCCCC(O)C(=O)OC(CC)CCCCC
PREFCHVVKZWHMM-UHFFFAOYSA-N
0.000
description
2


229940093440
oleth-3-phosphate
Drugs




0.000
description
2


229940093446
oleth-5
Drugs




0.000
description
2


229940055577
oleyl alcohol
Drugs




0.000
description
2


BARWIPMJPCRCTP-CLFAGFIQSA-N
oleyl oleate
Chemical compound


CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC
BARWIPMJPCRCTP-CLFAGFIQSA-N
0.000
description
2


239000004006
olive oil
Substances




0.000
description
2


235000008390
olive oil
Nutrition




0.000
description
2


125000000913
palmityl group
Chemical group


[H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]

0.000
description
2


PXDJXZJSCPSGGI-UHFFFAOYSA-N
palmityl palmitate
Chemical compound


CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC
PXDJXZJSCPSGGI-UHFFFAOYSA-N
0.000
description
2


239000002245
particle
Substances




0.000
description
2


230000037361
pathway
Effects




0.000
description
2


239000000312
peanut oil
Substances




0.000
description
2


230000000149
penetrating
Effects




0.000
description
2


239000002831
pharmacologic agent
Substances




0.000
description
2


229920001993
poloxamer 188
Polymers




0.000
description
2


229920001992
poloxamer 407
Polymers




0.000
description
2


229920000435
poly(dimethylsiloxane)
Polymers




0.000
description
2


239000008389
polyethoxylated castor oil
Substances




0.000
description
2


229920000059
polyethylene glycol stearate
Polymers




0.000
description
2


235000010486
polyoxyethylene sorbitan monolaurate
Nutrition




0.000
description
2


239000000256
polyoxyethylene sorbitan monolaurate
Substances




0.000
description
2


235000010482
polyoxyethylene sorbitan monooleate
Nutrition




0.000
description
2


239000000244
polyoxyethylene sorbitan monooleate
Substances




0.000
description
2


235000010483
polyoxyethylene sorbitan monopalmitate
Nutrition




0.000
description
2


239000000249
polyoxyethylene sorbitan monopalmitate
Substances




0.000
description
2


235000010989
polyoxyethylene sorbitan monostearate
Nutrition




0.000
description
2


239000001818
polyoxyethylene sorbitan monostearate
Substances




0.000
description
2


235000010988
polyoxyethylene sorbitan tristearate
Nutrition




0.000
description
2


239000001816
polyoxyethylene sorbitan tristearate
Substances




0.000
description
2


229940101027
polysorbate 40
Drugs




0.000
description
2


229940113124
polysorbate 60
Drugs




0.000
description
2


229920000053
polysorbate 80
Polymers




0.000
description
2


RMGVATURDVPNOZ-UHFFFAOYSA-M
potassium;hexadecyl hydrogen phosphate
Chemical compound


[K+].CCCCCCCCCCCCCCCCOP(O)([O-])=O
RMGVATURDVPNOZ-UHFFFAOYSA-M
0.000
description
2


230000003389
potentiating
Effects




0.000
description
2


230000002265
prevention
Effects




0.000
description
2


239000000651
prodrug
Substances




0.000
description
2


229940002612
prodrugs
Drugs




0.000
description
2


NEOZOXKVMDBOSG-UHFFFAOYSA-N
propan-2-yl 16-methylheptadecanoate
Chemical compound


CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C
NEOZOXKVMDBOSG-UHFFFAOYSA-N
0.000
description
2


ATUOYWHBWRKTHZ-UHFFFAOYSA-N
propane
Chemical compound


CCC
ATUOYWHBWRKTHZ-UHFFFAOYSA-N
0.000
description
2


239000001294
propane
Substances




0.000
description
2


229940093625
propylene glycol monostearate
Drugs




0.000
description
2


125000004805
propylene group
Chemical group


[H]C([H])([H])C([H])([*:1])C([H])([H])[*:2]

0.000
description
2


239000001944
prunus armeniaca kernel oil
Substances




0.000
description
2


FSYKKLYZXJSNPZ-UHFFFAOYSA-N
sarcosine zwitterion
Chemical compound


C[NH2+]CC([O-])=O
FSYKKLYZXJSNPZ-UHFFFAOYSA-N
0.000
description
2


231100000241
scar
Toxicity




0.000
description
2


230000037387
scars
Effects




0.000
description
2


239000002453
shampoo
Substances




0.000
description
2


KEAYESYHFKHZAL-UHFFFAOYSA-N
sodium
Chemical compound


[Na]
KEAYESYHFKHZAL-UHFFFAOYSA-N
0.000
description
2


239000011734
sodium
Substances




0.000
description
2


229910052708
sodium
Inorganic materials




0.000
description
2


FNAQHDAADHAGHX-UHFFFAOYSA-M
sodium;2-dodecoxyethyl hydrogen phosphate
Chemical compound


[Na+].CCCCCCCCCCCCOCCOP(O)([O-])=O
FNAQHDAADHAGHX-UHFFFAOYSA-M
0.000
description
2


239000000243
solution
Substances




0.000
description
2


235000011069
sorbitan monooleate
Nutrition




0.000
description
2


239000001593
sorbitan monooleate
Substances




0.000
description
2


229940035049
sorbitan monooleate
Drugs




0.000
description
2


235000011071
sorbitan monopalmitate
Nutrition




0.000
description
2


239000001570
sorbitan monopalmitate
Substances




0.000
description
2


229940031953
sorbitan monopalmitate
Drugs




0.000
description
2


235000011076
sorbitan monostearate
Nutrition




0.000
description
2


239000001587
sorbitan monostearate
Substances




0.000
description
2


229940035048
sorbitan monostearate
Drugs




0.000
description
2


229940114926
stearate
Drugs




0.000
description
2


239000000126
substance
Substances




0.000
description
2


238000003786
synthesis reaction
Methods




0.000
description
2


230000002194
synthesizing
Effects




0.000
description
2


239000003760
tallow
Substances




0.000
description
2


KRIXEEBVZRZHOS-UHFFFAOYSA-L
tetradecyl phosphate
Chemical compound


CCCCCCCCCCCCCCOP([O-])([O-])=O
KRIXEEBVZRZHOS-UHFFFAOYSA-L
0.000
description
2


230000037317
transdermal delivery
Effects




0.000
description
2


150000003626
triacylglycerols
Chemical class




0.000
description
2


FDGZUBKNYGBWHI-UHFFFAOYSA-N
trioctadecyl phosphate
Chemical compound


CCCCCCCCCCCCCCCCCCOP(=O)(OCCCCCCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC
FDGZUBKNYGBWHI-UHFFFAOYSA-N
0.000
description
2


230000002792
vascular
Effects




0.000
description
2


230000035513
volume of distribution
Effects




0.000
description
2


239000001993
wax
Substances




0.000
description
2


239000000080
wetting agent
Substances




0.000
description
2


239000000230
xanthan gum
Substances




0.000
description
2


229920001285
xanthan gum
Polymers




0.000
description
2


235000010493
xanthan gum
Nutrition




0.000
description
2


229940082509
xanthan gum
Drugs




0.000
description
2


FLJBXFWRAHVQJH-DWEHOVEISA-N
CCCCCCCC/C=C\CCCCCCCCOCCOP(=O)(O)O.CCCCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCOP(=O)(O)OCCCCCCCCCCCCCCCC
Chemical compound


CCCCCCCC/C=C\CCCCCCCCOCCOP(=O)(O)O.CCCCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCOP(=O)(O)OCCCCCCCCCCCCCCCC
FLJBXFWRAHVQJH-DWEHOVEISA-N
0.000
description
1


0
[1*]C1=C([2*])C=C(C(=O)N([3*])[H])C=C1
Chemical compound


[1*]C1=C([2*])C=C(C(=O)N([3*])[H])C=C1

0.000
description
1



Images























































































































































Classifications




A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K9/00—Medicinal preparations characterised by special physical form


A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels








A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/12—Ketones


A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/16—Amides, e.g. hydroxamic acids


A61K31/17—Amides, e.g. hydroxamic acids having the group >NâC(O)âN< or >NâC(S)âN<, e.g. urea, thiourea, carmustine







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids


A61K31/19—Carboxylic acids, e.g. valproic acid


A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/33—Heterocyclic compounds


A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin


A61K31/365—Lactones


A61K31/366—Lactones having six-membered rings, e.g. delta-lactones







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/33—Heterocyclic compounds


A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins


A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom


A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/33—Heterocyclic compounds


A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins


A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines


A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim


A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings


A61K31/52—Purines, e.g. adenine







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/33—Heterocyclic compounds


A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins


A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines


A61K31/5375—1,4-Oxazines, e.g. morpholine


A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids


A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone


A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K31/00—Medicinal preparations containing organic active ingredients


A61K31/60—Salicylic acid; Derivatives thereof







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00Â -Â A61K41/00


A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient


A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite


A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides


A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient


A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite


A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides


A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient


A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite


A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient


A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates


A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit


A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K9/00—Medicinal preparations characterised by special physical form


A61K9/0012—Galenical forms characterised by the site of application


A61K9/0014—Skin, i.e. galenical aspects of topical compositions







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES


A61K9/00—Medicinal preparations characterised by special physical form


A61K9/10—Dispersions; Emulsions


A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS


A61P17/00—Drugs for dermatological disorders







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS


A61P17/00—Drugs for dermatological disorders


A61P17/06—Antipsoriatics







A—HUMAN NECESSITIES


A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE


A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS


A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]







Abstract

Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.




Description

CROSS REFERENCE TO RELATED APPLICATIONS
   This application claims the benefit of U.S. Provisional Application No. 62/680,203 filed Jun. 4, 2018 and U.S. Provisional Application No. 62/742,644 filed on Oct. 8, 2018, the disclosures of which are incorporated herein in their entirety by reference.
 BACKGROUND OF INVENTION
   Pharmacokinetics is the study of the movement of a drug within a patient's body over time. There are four phases used to determine the pharmacokinetics of a drug, absorption, distribution, metabolism and excretion. Absorption after topical application is the process of drug movement from the application site across one or more cell membrane barriers into the circulation. The absorption of topically administered drugs is important for dermatological treatments and for topical application of systemic medications. After topical administration, the drugs must first be absorbed into the skin. Drug metabolism can occur in the skin or the drug may reach the systemic circulation before it is metabolized. After a topically administered drug reaches the systemic circulation, its fate is similar to that of systemically administered drugs. The concentrations of a drug that reach the target site after topical administration is highly dependent on the characteristics of both the drug itself and its formulation, as well as the characteristics of the patient's skin.
    The healthy skin of a pig or human will absorb a pharmaceutical active from a topically applied semisolid in a very predictable way. Following the onset of skin exposure to a compound, the cumulative influx into the skin follows the time course shown in FIG. 1(a), whereas the outflux of the same compound into the vasculature displays a time course shown in FIG. 1(b). The influx rate starts at a higher rate because there is initially no compound in the skin, or more precisely no drug is in the intercellular spaces of the stratum corneum. The higher influx rate is due to the concentration of drug in a non-volatile product being at its highest concentration upon initial dosing of the topical semisolid which results in the thermodynamic driving force of drug influx into the skin being at its maximum. At this point, the outflux into the vasculature is negligible.
    Robinson defines âlag timeâ this way (P. J. Robinson, âPredictionâSimple Risk Models and Overview of Dermal Risk Assessmentâ Chapter 8, pages 203-229 in Dermal Absorption and toxicity Assessment edited by Michael S. Roberts and Kenneth A. Walters. Marcel Dekker, New York 1998 page 215): âAfter a while, drug builds up in the skin and outflux into the blood increases. Eventually, sufficient material builds up in the skin itself that a steady state is reached in which influx into the skin equals outflux from the skin into the vasculature. After such a âlag timeâ, which depends on the compound and may be an hour or more, the curves (a) and (b) have the same slope (given essentially by the dermal penetration coefficient Kp).â It should be noted that the total amount of drug that has entered the skin (influx) is always greater than the amount of drug that has entered the vasculature (outflux). In other words, curve (a) in FIG. 1 is always above curve (b).
    Mathematically, the dermal penetration coefficient Kp can be solved using Fick's Laws of Diffusion derived by Adolf Fick in 1855.
    For clinically relevant dosing in which a finite amount of topical semisolid is rubbed into diseased skin, the cumulative influx of active into the skin (FIG. 2a ) and outflux into the vasculature (FIG. 2b ) will have a significantly different time course. Since the duration of exposure to a compound is limited, a plateau occurs in the time course curve for influx into the skin, which is mirrored by a plateau in the outflux into the vasculature curve. For a single dose application, eventually the two plateau lines will become parallel with the difference in magnitude representing the percent of applied dose absorbed. As a practical matter, when a patient is being treated topically for a skin disease, a second dose is applied prior to the cumulative skin influx curve and cumulative vasculature outflux curve becoming truly parallel. However, two aspects of how a topically applied pharmaceutical active penetrates skin rigorously holds; 1) a lag time exists between influx into the skin and outflux into the vasculature and 2) the amount of drug entering the skin is always greater than the amount of drug entering the vasculature. These two rules apply to dosing humans or mammals either ex vivo, in vitro, or in vivo using clinically relevant finite dosing or infinite dosing used in in vitro membrane diffusion experiments.
    To better understand the first aspect of topical skin penetration stated above, it should be noted that the lag time between influx into the skin and outflux into the vasculature measured using in vitro penetration testing (IVPT) can be dramatically shorter compared to the lag time for the active to achieve measurable blood concentrations in a pharmacokinetic (PK) study. For IVPT, excised human skin is cut to a depth of 200-600 micrometers which assures an intact stratum corneum and skin barrier, but cuts away the lower dermis that resides below the network of skin vasculature that removes actives from the skin, i.e. vascular outflux. The skin is cut using a dermatome and mounted on a diffusion cell that allows dosing of a formulation onto the stratum corneum and sampling of a receptor solution in contact with the cut surface of the dermis. The time point that measurable concentrations of active appears in the receptor solution can be extrapolated to calculate the lag time with the assumption that the time course of passive diffusion through the stratum corneum, epidermis and upper dermis is similar for excised skin and intact skin of a subject being dosed topically. For a PK study, once active has entered the vasculature and skin outflux has begun, multiple mechanisms dilute or remove the active from the blood to concentrations below the bioanalytical method detection limit. Since PK sampling is completed remotely from the site of topical product application (dose the back, but pull blood from the arm), the initial outflux is diluted by the blood volume of the subject (mammal or human) being studied. The drug outfluxed from the skin into the vasculature will then undergo distribution into the tissues, metabolism and excretion characteristic of the drug further delaying detection in the blood and extending lag time. These PK parameters, such as volume of distribution and drug half-life are characterized using intravenous dosing of the drug and contrasted to results after topical application to determine dermal bioavailability of the topically applied dermatological formulation (M. S. Roberts and K. A. Walters, âThe Relationship Between Structure and Barrier Function of Skinâ Chapter 1, pages 1-42 in Dermal Absorption and toxicity Assessment edited by Michael S. Roberts and Kenneth A. Walters. Marcel Dekker, New York 1998 page 21). Thus, the lag time measured using IVPT is shorter than the lag time measured in PK experiments, because achieving measurable blood levels of active always takes longer than for active to diffuse to the depth in the skin required to reach the vasculature for outflux from the skin.
    As stated above in the quote from Robinson, it is well established that lag time depends on the compound penetrating the skin and may be an hour or more. It is also well established that skin penetration enhancers (Osborne & Henke reference), excipients combined with the pharmaceutical active to formulate a topical product, can influence lag time as well as increase the amount of active crossing the stratum corneum. For this reason, scientists that develop topical pharmaceutical products often use IVPT to screen multiple prototype formulations to select which final composition to advance into the non-clinical and clinical studies required to advance a dermatological product through the approval process. During development of topical roflumilast for the treatment of inflammatory skin conditions, it was discovered that roflumilast dissolved in a topically applied formulation containing an emulsifier, wherein the formulation has a pH value between 4.0-6.5 had a surprisingly short lag time of less than 1 hour when applied to a living mammal.
    Roflumilast and its synthesis were described in U.S. Pat. No. 5,712,298 (the â'298 patentâ), incorporated herein by reference (*unless otherwise indicated, all references incorporated herein by reference are incorporated in their entireties for all purposes). It has long been recognized that pharmaceutical compounds having phosphodiesterase (PDE)-inhibiting properties, such as roflumilast, are useful for treating psoriasis and atopic dermatitis ('298 patent, col 11 lines 52-61) and other chronic inflammatory and allergen-induced dermatoses. For treatment of such dermatoses, roflumilast emulsions, suspensions, gels or solutions for topical application have been described ('298 patent, col 12, lines 37-64).
    Topical application of potent pharmacological agents like roflumilast for treating skin diseases has been found to provide superior delivery, lower systemic exposure and greater ease of use for patients. The molecular structure of the compound ultimately dictates the ability of the drug to cross the epithelium of the tissue to which the product is applied. For topical application to skin, selection of the components of the formulation dictates the maximum skin permeation that the formulator can achieve. Creams, lotions, gels, ointments and foams are just a few of the more familiar forms of topical products that contain active pharmaceutical ingredients (API) for application to the skin.
    The ability of a dissolved active ingredient to permeate the barrier of the skin is determined by its molecular structure. A well-known relationship between molecular structure and skin penetration is that increasing molecular weight decreases the rate that an active crosses the skin (J D Bos, M M Meinardi, Exp Dermatol. 2000 June; 9(3):165-9).
    Another well-understood relationship is that increasing the octanol-water partition coefficient of a hydrophilic active initially increases the rate that an active permeates the skin, but then decreases skin permeation once the active becomes too lipophilic to partition out of the stratum corneum and into the lower layers of the epidermis (D. W. Osborne and W. J. Lambert, Prodrugs for Dermal Delivery, K. B. Sloane ed., Marcel Dekker, New York 163-178 (1992)). The optimal octanol-water partition coefficient is usually at log P values of 2-3. The rate that an active ingredient crosses into the viable epidermis can be further modified based on the composition of the topical product. Final pH of the formulation may be critical, because dissolved ionized active ingredients typically do not permeate the skin as effectively as active ingredients that do not carry a charge (N. Li, X. Wu, W. Jia, M. C. Zhang, F. Tan, and J Zhang. Drug Dev Indust Pharm 38(8)985-994). Functional ingredients such as skin penetration enhancers (D. W. Osborne and J. J. Henke, Pharmaceutical Technology 21(11)58-66(1997)) can be added to the topical product to increase skin permeation. For a dissolved active in the topical product, the closer the drug concentration is to the amount of active required to saturate the drug product, the greater the thermodynamic driving force of the active to cross the skin, i.e. the greater the skin flux of the active. The scientific literature guides formulators on how to increase penetration through the polar route, the nonpolar route, and the intercellular lipid pathway or transfollicular penetration.
    A method for decreasing skin penetration lag times will improve the bioavailability of topically administered roflumilast thereby improving the treatment outcome of topically treated skin conditions.
 
BRIEF DESCRIPTION OF THE DRAWINGS
    FIG. 1 shows an idealized influx curve (a) compared to throughflux curve (b) after infinite dosing (Adapted from Robinson).
     FIG. 2 shows an idealized influx curve (a) compared to throughflux curve (b) after finite dosing.
     FIG. 3 shows that the five creams containing Crodafos CES as the emulsifier had measurable levels of roflumilast in the receptor solution one hour after dosing. These creams had essentially the same extrapolated lag times in the range of 50-60 minutes, slightly less than 1 hour when adjusted to pH values between 5.0 and 6.5.
 
SUMMARY OF THE INVENTION
   In accordance with the present invention, it has been discovered that maintaining topically applied roflumilast at a pH value between 4.0-6.5 and/or combining roflumilast with specific emulsifiers results in skin penetration lag times of less than one hour. The surprisingly short lag time is particularly important in topically treating inflammatory skin conditions since it not only provides quicker onset of disease relief, but also allows for more consistent bioavailability of active since roflumilast spends less time on the skin surface, vulnerable to transference to clothing or other people.
 DETAILED DESCRIPTION OF THE INVENTION
   Roflumilast is a compound of the formula (I)
  



 
 



  wherein R1 is difluoromethoxy, R2 is cyclopropylmethoxy and R3 is 3,5-dichloropyrid-4-yl.
    This compound has the chemical name N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamid-e (INN: roflumilast). Roflumilast can be prepared by methods known in the art (e.g. see the '298 patent and U.S. application Ser. No. 14/075,035).
    Diethylene glycol monoethyl ether is a compound of the formula (II)
  



 
 



    The emulsifier blend of cetearyl alcohol (CAS 67762 30 0), dicetyl phosphate (CAS 2197 63 9) and ceteth-10 phosphate (CAS 50643-20-4) which is manufactured by Croda under the tradename CRODAFOSâ¢ CES. This commercially available emulsifier blend is a self-emulsifying wax that is predominately the waxy material cetearyl alcohol (which is a mixture cetyl alcohol (C16H34O) and stearyl alcohol (C18H38O)) combined with 10-20% dicetyl phosphate and 10-20% ceteth-10 phosphate. Self-emulsifying waxes form an emulsion when blended with water. When CRODAFOSâ¢ CES is added to water it spontaneously forms an emulsion having a pH of about 3. Sodium hydroxide solution is added to increase the pH to the desired value.
  



 
 



    The present invention is directed to pharmaceutical compositions of roflumilast with the pH value adjusted to 4.0-6.5. In a preferred embodiment, roflumilast can be blended with diethylene glycol monoethyl ether (DEGEE, Gattefosse Tradename TRANSCUTOLÂ®) and water. This pH adjusted aqueous DEGEE blend optionally includes one or more pharmaceutically acceptable carriers. Any suitable grade of TRANSCUTOLÂ® can be used including TRANSCUTOLÂ®P, TRANSCUTOLÂ®HP, TRANSCUTOLÂ®V and TRANSCUTOLÂ®CG. This blend of DEGEE and water can undergo the addition of excipients and further processing to form a range of pharmaceutical dosage forms and maintain dissolved or molecularly dispersed roflumilast over the shelf life of the drug product. In another embodiment, hexylene glycol can be included in the roflumilast composition.
    The present invention is also directed to pharmaceutical compositions of roflumilast blended with self-emulsifying wax blends of cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate (Croda Tradename CRODAFOSâ¢ CES) and water with the pH value adjusted to between 4.0-6.5. This pH adjusted aqueous phosphate-ester based emulsifying wax optionally includes one or more pharmaceutically acceptable carriers. Any suitable grade of CRODAFOSâ¢ can be used including CRODAFOSâ¢ CES-PA and CRODAFOSâ¢ CS20A. This blend of phosphate-ester self-emulsifying wax and water can undergo the addition of excipients and further processing to form a range of pharmaceutical dosage forms and maintain dissolved or molecularly dispersed roflumilast over the shelf life of the drug product.
    The present invention is also directed to pharmaceutical compositions of roflumilast blended with DEGEE and the self-emulsifying wax blend of cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate and water with the pH value adjusted to 4.0-6.5.
    The present invention is particularly useful for topical formulations. The topical roflumilast pharmaceutical product formulations that could be based on DEGEE-water blends are defined in U.S. Pharmacopeia USP <1151> and include aerosols, foams, sprays, emulsions (which can also be called creams, lotions, or ointments), gels (two phase or single phase), liquids, ointments, pastes, shampoos, suspensions, and systems. These are typical dosage forms containing pharmaceutically active ingredients for topical application to mammals, including humans.
    Topical application refers to dosing the skin, hair or nails of a patient that will benefit from treatment with a pharmaceutical product. Topical can also mean application to the epithelium of the patient for localized delivery. This includes but is not limited to ophthalmic, ottic, oral mucosa, vaginal mucosa, rectal mucosa or urethral application of roflumlast. The broadest definition of topical would include using the epithelium of a patient as a route of administration to obtain therapeutic systemic levels of the active ingredient. This definition of topical is often referred to as transdermal delivery of therapeutic active ingredients.
    The roflumilast formulations can be prepared by methods known in the art (e.g. see the '298 patent and U.S. application Ser. No. 14/075,035).
    DEGEE is often formulated as 10-30% (w/w), preferably 15-20% (w/w), in topical formulations. Likewise, water is formulated as about 20-90% (w/w) in topical products. For blends of DEGEE and water the ratio can range from 1:10 to 20:1. Preferably the DEGEE:water ratio is 1:4 to 9:1 in a formulation containing roflumilast.
    Generally, DEGEE-water blends can be used to dissolve up to 2.0% roflumilast (in the finished product) or preferably up to 0.5% roflumilast (in the finished product). The finished product is preferably in one of the following forms:
    An oil-in-water emulsion: The topical product may be an emulsion comprising a discrete hydrophobic phase and a continuous aqueous phase that includes the DEGEE-water blend and optionally one or more polar hydrophilic excipients as well as solvents, co-solvents, salts, surfactants, emulsifiers, and other components. These emulsions may include water-soluble or water-swellable polymers that help to stabilize the emulsion.
    A water-in-oil emulsion: The compositions may be formulations in which roflumilast is incorporated into an emulsion that includes a continuous hydrophobic phase and an aqueous phase that includes the DEGEE-water blend and optionally one or more polar hydrophilic carrier(s) as well as salts or other components. These emulsions may include oil-soluble or oil-swellable polymers as well as one or more emulsifier(s) that help to stabilize the emulsion.
    For both oil-in-water and water-in-oil emulsions, order of addition may be important. Roflumilast can be added pre-dissolved in the continuous aqueous phase containing the DEGEE-water blend. Likewise, roflumilast can be pre-dissolved in the hydrophobic discrete phase of the emulsion that is then mixed with the DEGEE-water blend and optional hydrophilic excipients that do not contain the active ingredient. Roflumilast can be pre-dissolved in both the oil phase and water phase of the emulsion or added pre-dissolved in DEGEE or a DEGEE-water blend after the emulsion has been formed. Some emulsions undergo phase inversion over a specific temperature range during cooling of the emulsion. Thus, roflumilast may be added to a water-in-oil emulsion above the phase inversion temperature, with the final drug product being an oil-in-water emulsion at controlled room temperature, or vice versa.
    Thickened aqueous gels: These systems include the DEGEE-water blend with dissolved roflumilast and optionally one or more polar hydrophilic carrier(s) such as hexylene glycol which has been thickened by suitable natural, modified natural, or synthetic thickeners as described below. Alternatively, the thickened aqueous gels can be thickened using suitable polyethoxylate alky chain surfactants or other nonionic, cationic, or anionic systems.
    Thickened hydroalcoholic gels: These systems include the DEGEE-water-alcohol blend with dissolved roflumilast and optionally one or more polar hydrophilic carrier(s) such as hexylene glycol as the polar phase which has been thickened by suitable natural, modified natural, or synthetic polymers such as described below. Alternatively, the thickened hydroalcoholic gels can be thickened using suitable polyethoxylate alky chain surfactants or other nonionic, cationic, or anionic systems. The alcohol can be ethanol, isopropyl alcohol or other pharmaceutically acceptable alcohol.
    A hydrophilic or hydrophobic ointment: The compositions are formulated with a hydrophobic base (e.g. petrolatum, thickened or gelled water insoluble oils, and the like) and optionally have a minor amount of the DEGEE-water blend with dissolved roflumilast. Hydrophilic ointments generally contain one or more surfactants or wetting agents.
 Solvents
   Compositions of the present invention may include one or more solvents or co-solvents to obtain the desired level of active ingredient solubility in the product. The solvent may also modify skin permeation or activity of other excipients contained in a topical product. Solvents include but are not limited to acetone, ethanol, benzyl alcohol, butyl alcohol, diethyl sebacate, diethylene glycol monoethyl ether, diisopropyl adipate, dimethyl sulfoxide, ethyl acetate, isopropyl alcohol, isopropyl isostearate, isopropyl myristate, N-methyl pyrrolidinone, propylene glycol and SD alcohol.
 Moisturizers
   Compositions of the present invention may include a moisturizer to increase the level of hydration. For emulsions, the moisturizer is often a component of the discrete or continuous hydrophobic phase. The moisturizer can be a hydrophilic material including humectants or it can be a hydrophobic material including emollients. Suitable moisturizers include but are not limited to: 1,2,6-hexanetriol, 2-ethyl-1,6-hexanediol, butylene glycol, glycerin, polyethylene glycol 200-8000, butyl stearate, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, cetyl palmitate, cocoa butter, coconut oil, cyclomethicone, dimethicone, docosanol, ethylhexyl hydroxystearate, fatty acids, glyceryl isostearate, glyceryl laurate, glyceryl monostearate, glyceryl oleate, glyceryl palmitate, glycol distearate, glycol stearate, isostearic acid, isostearyl alcohol, lanolin, mineral oil, limonene, medium-chain triglycerides, menthol, myristyl alcohol, octyldodecanol, oleic acid, oleyl alcohol, oleyl oleate, olive oil, paraffin, peanut oil, petrolatum, Plastibase-50W, and stearyl alcohol.
    Surfactants and Emulsifiers
    Compositions according to the present invention can optionally include one or more surfactants to emulsify the composition and to help wet the surface of the active ingredients or excipients. As used herein the term âsurfactantâ means an amphiphile (a molecule possessing both polar and nonpolar regions which are covalently bound) capable of reducing the surface tension of water and/or the interfacial tension between water and an immiscible liquid. Surfactants include but are not limited to alkyl aryl sodium sulfonate, Amerchol-CAB, ammonium lauryl sulfate, apricot kernel oil PEG-6 esters, Arlacel, benzalkonium chloride, Ceteareth-6, Ceteareth-12, Ceteareth-15, Ceteareth-30, cetearyl alcohol/ceteareth-20, cetearyl ethylhexanoate, ceteth-10, ceteth-10 phosphate, ceteth-2, ceteth-20, ceteth-23, choleth-24, cocamide ether sulfate, cocamine oxide, coco betaine, coco diethanolamide, coco monoethanolamide, coco-caprylate/caprate, dicetyl phosphate, disodium cocoamphodiacetate, disodium laureth sulfosuccinate, disodium lauryl sulfoacetate, disodium lauryl sulfosuccinate, disodium oleamido monoethanolamine sulfosuccinate, docusate sodium, laureth-2, laureth-23, laureth-4, lauric diethanolamide, lecithin, mehoxy PEG-16, methyl gluceth-10, methyl gluceth-20, methyl glucose sesquistearate, oleth-2, oleth-20, PEG 6-32 stearate, PEG-100 stearate, PEG-12 glyceryl laurate, PEG-120 methyl glucose dioleate, PEG-15 cocamine, PEG-150 distearate, PEG-2 stearate, PEG-20 methyl glucose sesqustearate, PEG-22 methyl ether, PEG-25 propylene glycol stearate, PEG-4 dilaurate, PEG-4 laurate, PEG-45/dodecyl glycol copolymer, PEG-5 oleate, PEG-50 Stearate, PEG-54 hydrogenated castor oil, PEG-6 isostearate, PEG-60 hydrogenated castor oil, PEG-7 methyl ether, PEG-75 lanolin, PEG-8 laurate, PEG-8 stearate, Pegoxol 7 stearate, pentaerythritol cocoate, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 188, poloxamer 237 poloxamer 407, polyglyceryl-3 oleate, polyoxyethylene alcohols, polyoxyethylene fatty acid esters, polyoxyl 20 cetostearyl ether, polyoxyl 40 hydrogenated castor oil, polyoxyl 40 stearate, polyoxyl 6 and polyoxyl 32, polyoxyl glyceryl stearate, polyoxyl stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 65, polysorbate 80, PPG-26 oleate, PROMULGENâ¢ 12, propylene glycol diacetate, propylene glycol dicaprylate, propylene glycol monostearate, sodium xylene sulfonate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, steareth-2, steareth-20, steareth-21, steareth-40, tallow glycerides, and emulsifying wax. The formulation preferably contains one or more phosphate ester surfactants. Examples of phosphate ester surfactants that may be included in the formulation include but are not limited to potassium cetyl phosphate, potassium C9-15 alkyl phosphate, potassium C11-15 alkyl phosphate, potassium C12-13 alkyl phosphate, potassium C12-14 alkyl phosphate, potassium lauryl phosphate, C8-10 alkyl ethyl phosphate, C9-15 alkyl phosphate, C20-22 alkyl phosphate, castor oil phosphate, ceteth-10 phosphate, cetheth-20 phosphate, ceteth-8 phosphate, cetearyl phosphate, cetyl phosphate, dimethicone PEG-7 phosphate, disodium lauryl phosphate, disodium oleyl phosphate, lauryl phosphate, myristyl phosphate, octyldecyl phosphate, oleth-10 phosphate, oleth-5 phosphate, oleth-3 phosphate, oleyl ethyl phosphate oleyl phosphate, PEG-26-PPG-30 phosphate, PPG-5ceteareth-10 phosphate, PPG-5 ceteth-10 phosphate, sodium lauryl phosphate, sodium laureth-4 phosphate, steartyl phosphate, DEA-cetyl phosphate, DEA-oleth-10 phosphate, DEA-oleth-3 phosphate, DEA-C8-C18 perfluoroalkylethyl phosphate, dicetyl phosphate, dilaureth-10 phosphate, dimyristyl phosphate, dioleyl phosphate, tricetyl phosphate, triceteareth-4 phosphate, trilaureth-4 phosphate, trilauryl phosphate, triolyeyl phosphate and tristearyl phosphate.
 Polymers and Thickeners
   For certain applications, it may be desirable to formulate a topical product that is thickened with soluble, swellable, or insoluble organic polymeric thickeners such as natural and synthetic polymers or inorganic thickeners including but not limited to acrylates copolymer, carbomer 1382, carbomer copolymer type B, carbomer homopolymer type A, carbomer homopolymer type B, carbomer homopolymer type C, caroboxy vinyl copolymer, carboxymethylcellulose, carboxypolymethylene, carrageenan, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, microcrystalline wax, and methylcellulose.
 Additional Components
   Compositions according to the present invention may be formulated with additional components such as fillers, carriers and excipients conventionally found in cosmetic and pharmaceutical topical products. Additional components include but are not limited to antifoaming agents, propellants, preservatives, antioxidants, sequestering agents, stabilizers, buffers, pH adjusting solutions, skin penetration enhancers, film formers, dyes, pigments, fragrances and other excipients to improve the stability or aesthetics of the product. In a preferred embodiment, hexylene glycol is added to inhibit changes in particle size distribution over the shelf life of the composition. Hexylene glycol can be added between 0.1% and 20% on a weight/weight basis, preferably between 0.25% and 8% on a weight/weight basis and most preferably between 0.5% and 2% on a weight/weight basis.
    In one preferred embodiment, the roflumilast is in the form of an aerosolized foam which is particularly suitable for application to the scalp. Any suitable propellant can be used to prepare the aerosolized foam. Particularly preferred propellants are Isobutane A-31, Aeropin 35, Butane 48, Dimethyl Ether/N-Butane-(53/47), Propane/Iso-Butane/N-Butane, Propane/Isobutane-A70, and Propane/Isobutane A-46, N-Butane (A-17.
    Compositions according to the present invention may be formulated with additional active agents depending on the condition to be treated. The additional active agents include but are not limited to Anthralin (dithranol), Azathioprine, Tacrolimus, Coal tar, Methotrexate, Methoxsalen, Salicylic acid, Ammonium lactate, Urea, Hydroxyurea, 5-fluorouracil, Propylthouracil, 6-thioguanine, Sulfasalazine, Mycophenolate mofetil, Fumaric acid esters, Corticosteroids (e.g. Aclometasone, Amcinonide, Betamethasone, Clobetasol, Clocotolone, Mometasone, Triamcinolone, Fluocinolone, Fluocinonide, Flurandrenolide, Diflorasone, Desonide, Desoximetasone, Dexamethasone, Halcinonide, Halobetasol, Hydrocortisone, Methylprednisolone, Prednicarbate, Prednisone), Corticotropin, Vitamin D analogues (e.g. calcipotriene, calcitriol), Acitretin, Tazarotene, Cyclosporine, Resorcinol, Colchicine, Adalimumab, Ustekinumab, Infliximab, bronchodialators (e.g. beta-agonists, anticholinergics, theophylline), and antibiotics (e.g. erythromycin, ciprofloxacin, metronidazole).
 Administration and Dosage
   Suitable pharmaceutical dosage forms include but are not limited to emulsions, suspensions, sprays, oils, ointments, fatty ointments, creams, pastes, gels, foams transdermal patches and solutions (e.g. injectable, oral).
    The composition preferably contains roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof in an amount of 0.005-2% w/w, more preferably 0.05-1% w/w, and most preferably 0.1-0.5% w/w per dosage unit.
    The composition preferably contains diethylene glycol monoethyl ether in an amount of between 5% and 50% w/w, more preferably between 20% and 30% w/w and most preferably between 22.5% and 27.5% w/w.
    The composition can be administered one or more times per day, preferably the composition is administered 1-2 times per day.
    The composition can be used in veterinary and in human medicine for the treatment and prevention of all diseases regarded as treatable or preventable by using roflumilast, including but not limited to acute and chronic airway disorders; proliferative, inflammatory and allergic dermatoses; disorders which are based on an excessive release of TNF and leukotrienes; disorders of the heart which can be treated by PDE inhibitors; inflammations in the gastrointestinal system or central nervous system; disorders of the eye; arthritic disorders; and disorders which can be treated by the tissue-relaxant action of PDE inhibitors. Preferably, the composition is used to treat proliferative, inflammatory and allergic dermatoses such as psoriasis (vulgaris), eczema, acne, Lichen simplex, sunburn, pruritus, alopecia areata, hypertrophic scars, discoid lupus erythematosus, and pyodermias.
    The composition can include additional active agents suitable for treating the patient's condition. For example, when proliferative, inflammatory and allergic dermatoses are treated, the composition may additionally include Anthralin (dithranol), Azathioprine, Tacrolimus, Coal tar, Methotrexate, Methoxsalen, Salicylic acid, Ammonium lactate, Urea, Hydroxyurea, 5-fluorouracil, Propylthouracil, 6-thioguanine, Sulfasalazine, Mycophenolate mofetil, Fumaric acid esters, Corticosteroids (e.g. Aclometasone, Amcinonide, Betamethasone, Clobetasol, Clocotolone, Mometasone, Triamcinolone, Fluocinolone, Fluocinonide, Flurandrenolide, Diflorasone, Desonide, Desoximetasone, Dexamethasone, Halcinonide, Halobetasol, Hydrocortisone, Methylprednisolone, Prednicarbate, Prednisone), Corticotropin, Vitamin D analogues (e.g. calcipotriene, calcitriol), Acitretin, Tazarotene, Cyclosporine, Resorcinol, Colchicine, Adalimumab, Ustekinumab, Infliximab, and/or antibiotics.
    The following examples are provided to enable those of ordinary skill in the art to make and use the methods and compositions of the invention. These examples are not intended to limit the scope of what the inventors regard as their invention. Additional advantages and modifications will be readily apparent to those skilled in the art.
 Example 1
    
  






 
TABLE 1


 
 


 
1.0% Roflumilast 
Composition 


 
Cream Components 
% w/w


 
 



 
Roflumilast 
1.0, 0.5, 0.3, or 


 
 
0.15 


 
Petrolatum, USP 
10.0 


 
Isopropyl Palmitate, NF 
5.0 


 
Crodafos CES 
10.0 


 
cetostearyl alcohol 
 


 
dicetyl phosphate 
 


 
ceteth-10 phosphate 
 


 
Diethylene Glycol 
25.0 


 
Monoethyl Ether, NF 
 


 
(Transcutol P) 
 


 
Hexylene Glycol, NF 
2.0 


 
Methylparaben, NF 
0.20 


 
Propylparaben, NF 
0.050 


 
1N NaOH, NF 
q.s. ad pH 5.5 


 
Purified Water, USP   q.s. ad  100%


 
 





    Male and female swine (Gottingen MinipigÂ® breed) were ordered to weigh 8 to 12 kg at arrival. On the day prior to administration of topical cream containing 1.0% roflumilast, the hair was clipped from the back of each animal. Telazol (3 to 5 mg/kg, IM) was used to sedate the animals for the shaving procedure. Care was taken to avoid abrading the skin. 2 grams of cream for each kg of pig weight was distributed over the clipped skin area by gentle inunction with a glass stirring rod or appropriate instrument (e.g., stainless steel spatula). The cream was applied evenly with a thin, uniform film beginning at the scapular region and moving caudally over the test site. The width of the test site area was bilaterally divided by the spine. Equal numbers of male and female pigs were dosed with 1.0%, 0.5%, 0.3%, or 0.15% roflumilast cream. Blood was sampled from the anterior vena cava through the thoracic inlet or other suitable vein pre-dose (time=0), 1, 2, 4, 8 and 24 hours post dose administration. Lag times were calculated by extrapolating the average 1 hour and 2-hour plasma concentrations to the time point of zero roflumilast concentration in the plasma. For individual animals that had 1-hour plasma assays below the level of quantification (0.2 ng/mL), a value of 0.1 was used if the 2-hour PK time point was above 0.2 ng/mL. If the 2-hour PK time point was below the level of quantification, a value of 0 ng/mL was used for the individual animal to calculate the average. The lag time was less than 1 hour for each of the pH=5.5 roflumilast creams regardless of the concentration of roflumilast.
  





TABLE 2



 


Roflumilast
Extrapolated
Concentration of Roflumilast in Pig Plasma (ng/mL)




Creams pH = 5.5
 Lag Time 
1 hour
2 hours 
4 hours
8 hours
24 hours


 




1.0% cream 
55 min
0.1
0.9
1.6
1.08
0.7


(n = 20)


0.5% cream
47 min
0.2
1.1
1.2
1.0
0.6


(n = 12)


0.3% cream
38 min
0.2
0.8
0.7
0.8
0.3


(n = 6)


0.15% cream
47 min
0.2
1.1
0.4
0.4
0.2


(n = 12)


 





 Example 2
    
  





TABLE 3


 


PEG Cream
Composition
DES Cream
Composition
DIA Cream
Composition


 



 









Roflumilast
0.5%
w/w
Roflumilast
0.5%
w/w
Roflumilast
0.5%
w/w


Caprylic/Capric
16%
w/w
Diethyl
10%
w/w
Diisopropyl
15%
w/w


Triglyceride
 
 
Sebacate
 
 
Adipate


(MiglyolâÂ® 812)


Glycerol
8%
w/w
Light Mineral
0.7%
w/w
POE-7 Cocoyl
13.5%
w/w


Monostearate
 
 
 Oil   
 
Glycerides
 
Cremophor    
4%
w/w
Sorbitan
0.1%
w/w
Cetyl Alcohol
5%
w/w


A6âÂ®
 
 
Monooleate


Ceteareth-6


 Stearyl   
Alcohol


PEG    400
62.5%
w/w
Propylene
7.5%
w/w  Parafin  
1%
w/w


 
 
 
Glycol





Purified Water  q.s. ad  100%
Methylparaben
0.17%
w/w
Lanolin
2%
w/w





 
Propylparaben
0.03%
w/w  PEG  400
3%
w/w


 
Edetate
0.05%
w/w
Methylparaben
0.2%
w/w


 
Disodium


 
Pemulen TR-1
0.4%
w/w
Xanthan Gum
0.3%
w/w


 
Carbopol
0.6%
w/w
Disodium EDTA
0.1%
w/w


 
981


 
1 N NaOH
3.0%
w/w
Solan-75 PA 
3%
w/w






 
 Purified  q.s. ad  100%
Purified Water  q.s. ad  100%


 
Water


 
 





  





TABLE 4


 


0.05% Roflumilast 
 


Cream Components 
Composition (%) w/w


 



 





Roflumilast 
1.0 
0.15 
0.5 
0.5 
0.5 


Petrolatum, USP 
10.0 
10.0 
10.0 
10.0 
10.0 


Isopropyl Palmitate, 
5.0 
5.0 
5.0 
5.0 
5.0 


NF 
 
 
 
 
 


Crodafos CES 
10.0 
10.0 
10.0 
10.0 
10.0 


cetostearyl alcohol 
 
 
 
 
 


dicetyl phosphate 
 
 
 
 
 


ceteth-10 phosphate 
 
 
 
 
 


Diethylene Glycol 
25.0 
25.0 
25.0 
25.0 
25.0 


Monoethyl Ether, NF 
 
 
 
 
 


(Transcutol P) 
 
 
 
 
 


Hexylene Glycol, NF 
2.0 
2.0 
2.0 
2.0 
â


Methylparaben, NF 
0.20 
0.20 
0.20 
0.20 
0.20 


Propylparaben, NF 
0.050 
0.050 
0.050 
0.050 
0.050 


1N NaOH, NF 
q.s. ad 
q.s. ad 
q.s. ad 
q.s. ad 
q.s. ad 


 
pH 5.5 
pH 5.5 
pH 5.0 
pH 6.5 
pH 5.5 


Purified Water, USP 
q.s. ad 
q.s. ad 
q.s. ad 
q.s. ad   q.s. ad  


 
100% 
100% 
100% 
100% 
100%


 





    In vitro skin penetration testing (IVPT) was used to determine how rapidly eight different cream formulations crossed excised human skin. Human cadaver skin was procured from two donors (Caucasian male age=30 abdomen skin dermatomed to an average thickness of 510 Î¼m and Caucasian male age=55 abdomen skin dermatomed to an average thickness of 360 Î¼m). Dermatomed skin was received frozen from a US tissue bank and stored at â20Â° C. until use. Skin was loaded onto vertical Franz cells having a 0.503 cm2 (8 mm in diameter) diffusion area and a receptor chamber filled with 3.0 ml of 4% BSA in water containing 0.01% gentamicin sulfate thermostated at 32Â° C. Using a positive displacement pipette, 5 microliters of cream was dosed on each Franz Cell (10 mg per square centimeter of skin). Receptor solutions were analyzed using a validated LC-MS/MS (Kinetex C18, 5 Î¼m, 2.1Ã50 mm column, Shimadzu LC20ADXR pumps and AB Sciex API 4000 Turbo Spray detector). The cumulative amount of roflumilast assayed in the receptor solution is the average of four replicate IVPT measurements.
    As shown in FIG. 3, the five creams containing Crodafos CES as the emulsifier had measurable levels of roflumilast in the receptor solution one hour after dosing. These creams had essentially the same extrapolated lag times in the range of 50-60 minutes, slightly less than 1 hour when adjusted to pH values between 5.0 and 6.5. Removing hexylene glycol from the Crodafos CES cream formulation produced the product with the shortest lag time, i.e. the highest concentration of roflumilast (0.4 ng/mL) at 1 hour. It was concluded that hexylene glycol was not the excipient causing roflumilast to rapidly cross human stratum corneum, i.e. IVPT lag time of less than 1 hour.
    The DES, DIA and PEG creams did not transport significant amounts of roflumilast across human skin until three hours after the dose of cream was applied. Two of these three long lag time cream formulations contained methylparaben, one contained both methylparaben and propylparaben. It was concluded that the low levels of methylparaben and propylparaben required to preserve the creams did not shorten the lag time of roflumilast across the skin.
    The DES Cream contained light mineral oil and the DIA Cream contained paraffin. Mineral oil is the low molecular weight fraction of petrolatum and paraffin is the high molecular weight fraction of petrolatum. This indicated that the surprisingly short lag times of the Crodafos CES creams was due to either the cream containing Crodafos CES, DEGEE or a combination.
 Example 3
    
  





TABLE 5



 


 
Composition (% w/w) 




0.15% Roflumilast 
 
10% CES: 
 
25% 


Formulations 
Cream 
25% DEGEE 
10% CES 
DEGEE


 





Roflumilast 
0.15 
0.15 
0.15 
0.15 


Petrolatum, USP 
10 
â
â
â


Isopropyl Palmitate, NF 
5 
â
â
â


Crodafos CES 
10 
10 
10 
â


cetostearyl alcohol 
 
 
 
 


dicetyl phosphate 
 
 
 
 


ceteth-10 phosphate 
 
 
 
 


Diethylene Glycol 
25 
25 
â
25 


Monoethyl Ether, NF 
 
 
 
 


(Transcutol P) 
 
 
 
 


 
â
â
â
â


Hexylene Glycol, NF 
2 
â
â
â


Methylparaben, NF 
0.20 
â
â
â


Propylparaben, NF 
0.050 
â
â
â


1N NaOH, NF 
q.s. ad 
q.s. ad 
q.s. ad 
q.s. ad 


 
pH = 5.5 
pH 4.0 to 8.2 
pH = 6.5 
pH = 6.5 


Purified Water, USP 
q.s. ad 
q.s. ad 
q.s. ad   q.s. ad  


 
100% 
100% 
100% 
100%


 





    Male and female swine (Gottingen MinipigÂ® breed) were ordered to weigh 8 to 12 kg at arrival. On the day prior to administration of topical cream containing 0.15% roflumilast, the hair was clipped from the back of each animal. Telazol (3 to 5 mg/kg, IM) was used to sedate the animals for the shaving procedure. Care was taken to avoid abrading the skin. Two (2) grams of cream for each kg of pig weight was distributed over the clipped skin area by gentle inunction with a glass stirring rod or appropriate instrument (e.g., stainless steel spatula). The cream was applied evenly with a thin, uniform film beginning at the scapular region and moving caudally over the test site. The width of the test site area was bilaterally divided by the spine. Six pigs (3 males and 3 females) were dosed with 0.15% roflumilast topical semisolid products and twelve pigs (6 males and 6 females) were dosed with the 0.15% roflumilast cream. Blood was sampled from the anterior vena cava through the thoracic inlet or other suitable vein pre-dose (time=0), 1, 2, 4, 8 and 24 hours post dose administration. Lag times were calculated by extrapolating the average 1 hour and 2-hour plasma concentrations to the time point of zero roflumilast concentration in the plasma. For individual animals that had 1-hour plasma assays below the level of quantification (0.2 ng/mL), a value of 0.1 was used if the 2-hour PK time point was above 0.2 ng/mL. If the 2-hour PK time point was below the level of quantification, a value of 0 ng/mL was used for the individual animal to calculate the average. The lag time is less than 1 hour for all topical semisolid formulations at pH=6.5 or below and significantly greater than 1 hour for the semisolid having a pH value of 8.2.
  





TABLE 6



 


0.15% Roflumilast
Extrapolated
Concentration of Roflumilast in Pig Plasma (ng/mL)





Formulation
 pH  Lag Time  
1 hour
2 hours 
4 hours
8 hours
24 hours


 




10% CES:25%
4.0
47
min
0.2
0.4
0.4
0.3
0.1


DEGEE


Cream
5.5
47
min
0.2
1.1
0.4
0.4
0.2


10% CES:25%
6.5
<45
min
0.2
0.3
0.3
0.2
0.1


DEGEE


10% CES
6.5
<45
min
0.2
0.4
0.3
0.1
0


25% DEGEE
6.5
36
min
0.2
0.7
0.6
0.3
0.2


10% CES:25%
7.5
<45
min
0.2
0.3
0.4
0.3
0.1


DEGEE


10% CES:25%
8.2
>90
min
0
0.1
0.2
0.1
0.1


DEGEE


 





 Example 4
   A target amount of 480 grams Sterile Water for Irrigation-USP was accurately weighed into a 1000 ml glass beaker and 20 grams of Sodium Hydroxide Pellets-NF was added and mixed using a stir bar until complete dissolution. This solution was set aside and labeled 1 N Sodium Hydroxide.
    Target weights pf 1,000 grams White Petrolatum-USP, 500 grams Isopropyl Palmitate-NF, and 1,000 grams of phosphate-ester self-emulsifying wax (CRODAFOSâ¢ CES) was weighed into a 4 L glass beaker and heated on a hot plate to 75Â° C. to 80Â° C. while mixing with a propeller mixer. The mixture was labeled Oil Phase and was maintained at 75Â° C. to 80Â° C.
    To the Main Manufacturing Vessel (a 20 L stainless steel vessel) a target weight of 4,225 grams of Sterile Water for Irrigation-USP and a target weight 300 grams 1 N Sodium Hydroxide was added and heated on a hot plate to 75Â° C. to 80Â° C. This was recorded as the Aqueous Phase and was maintained at 75Â° C. to 80Â° C.
    Target weights of 2,400 grams of Transcutol P-NF, 200 grams of Hexylene Glycol-NF, 20.0 grams of Methylparaben-NF, and 5.0 grams of Propylparaben NF were accurately weighed into a 7 L stainless steel beaker and propeller mixed until a clear homogeneous solution was obtained. Sufficient potency corrected rofumilast (15.2120 grams) was added to this solution to obtain a 0.15% roflumilast cream and this was labeled the API Phase.
    The Oil Phase that was maintained at 75Â° C. to 80Â° C. was slowly added to the Aqueous Phase maintained at 75Â° C. to 80Â° C. in the Main Manufacturing Vessel with homogenizer mixing until a smooth, homogeneous cream was obtained. Using propeller mixing the cream was cooled to 45Â° C. to 50Â° C. The API Phase was slowly added to the cream in the main manufacturing vessel and was mixed with the homogenizer. The pH of the finished cream was measured and adjusted to within the pH range of 5.1 to 5.9 using 1 N Sodium Hydroxide or Diluted Hydrochloric Acid, 10% (w/v)-NF. After bulk product release, the cream was filled into aluminum Â¾â³Ã3Â¾â³ #16 sealed white tubes and the tubes crimped to provide the primary container closure system.
    13 human subjects having psoriasis (plaques not covering more than about 5% of the patient's body surface area) treated their skin lesions with the 0.15% Roflumilast cream formulation of example 3. One hour after the first application of topical cream a blood sample was taken, plasma separated and the concentration of roflumilast determined using a validated bioanalytical method. The average plasma concentration of roflumilast for these 13 subjects one hour after the first dose of topical cream was 0.398 ng roflumilast/mL of plasma. The lag time for psoriatic patients applying 0.15% roflumilast cream is less than 1 hour.
 Example 5
   The same manufacturing process used in Example 3 was performed except sufficient potency corrected rofumilast (50.69 grams) was added to API Phase solution to obtain a 0.5% roflumilast cream.
    15 human subjects having psoriasis (plaques not covering more than about 5% of the patient's body surface area) treated their skin lesions with the 0.5% Roflumilast cream formulation of example 2. One hour after the first application of topical cream a blood sample was taken, plasma separated and the concentration of roflumilast determined using a validated bioanalytical method. The average plasma concentration of roflumilast for these 15 subjects one hour after the first dose of topical cream was 0.595 ng roflumilast/mL of plasma. The lag time for psoriatic patients applying 0.5% roflumilast cream is less than 1 hour.
 



Claims (23)

 
 1. A method for reducing roflumilast skin penetration lag time in a patient, comprising topically administering a composition comprising roflumilast and an emulsifier blend to said patient, wherein said emulsifier blend comprises cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate, and wherein said composition has a pH between 4.0-6.5.

  
 2. The method according to claim 1, wherein said composition further comprises diethylene glycol monoethyl ether.

  
 3. The method according to claim 1, wherein said roflumilast composition comprises 0.005-2% roflumilast.

  
 4. The method according to claim 1, wherein said roflumilast skin penetration lag time is less than 60 minutes.

  
 5. The method according to claim 4, wherein said roflumilast skin penetration lag time is less than 45 minutes.

  
 6. The method according to claim 1, wherein said patient is suffering from an inflammatory condition.

  
 7. The method according to claim 1, wherein said patient is suffering from atopic dermatitis.

  
 8. A method for reducing roflumilast skin penetration lag time in a patient, comprising topically administering a composition comprising roflumilast and an agent selected from the group consisting of a) a phosphate ester surfactant, b) diethylene glycol monoethyl ether, c) isopropyl palmitate and combinations thereof, to a patient in need of such treatment.

  
 9. The method according to claim 8, wherein said composition has a pH between 4.0-6.5.

  
 10. The method according to claim 9, wherein said composition has a skin penetration lag time of less than 60 minutes.

  
 11. A pharmaceutical composition comprising roflumilast and an emulsifier blend, wherein said emulsifier blend comprises cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate, and wherein said composition has a pH between 4.0-6.5.

  
 12. The pharmaceutical composition according to claim 11, wherein said roflumilast is in an amount of 0.005-2% w/w.

  
 13. The pharmaceutical composition according to claim 12, wherein said roflumilast is in an amount of 0.05-1% w/w.

  
 14. The pharmaceutical composition according to claim 13, wherein said roflumilast is in an amount of 0.1-0.5% w/w.

  
 15. The pharmaceutical composition according to claim 14, wherein said roflumilast is in an amount of 0.3% w/w.

  
 16. The pharmaceutical composition according to claim 11, further comprising diethylene glycol monoethyl ether.

  
 17. The pharmaceutical composition according to claim 11, wherein said roflumilast composition is selected from the group consisting of an oil in water emulsion, a thickened aqueous gel, a thickened hydroalcoholic gel, a hydrophilic gel, and a hydrophilic or hydrophobic ointment.

  
 18. The pharmaceutical composition according to claim 11, wherein said roflumilast composition further comprises at least one additional component selected from the group consisting of a solvent, moisturizer, surfactant or emulsifier, polymer or thickener, antifoaming agent, preservative, antioxidant, sequestering agent, stabilizer, buffer, pH adjusting solution, skin penetration enhancer, film former, dye, pigment, and fragrance.

  
 19. The pharmaceutical composition according to claim 11, wherein said roflumilast composition further comprises an additional active agent selected from the group consisting of Anthralin, Azathioprine, Tacrolimus, Coal tar, Methotrexate, Methoxsalen, Salicylic acid, Ammonium lactate, Urea, Hydroxyurea, 5-fluorouracil, Propylthouracil, 6-thioguanine, Sulfasalazine, Mycophenolate mofetil, Fumaric acid esters, Corticosteroids, Corticotropin, Vitamin D analogues, Acitretin, Tazarotene, Cyclosporine, Resorcinol, Colchicine, Adalimumab, Ustekinumab, Infliximab, bronchodialators, and antibiotics.

  
 20. A pharmaceutical composition comprising roflumilast and at least one emulsifier, wherein said composition has a pH between 4.0-6.5.

  
 21. The pharmaceutical composition according to claim 20, further comprising diethylene glycol monoethyl ether.

  
 22. The pharmaceutical composition according to claim 20, wherein said emulsifier is an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.

  
 23. A pharmaceutical composition comprising roflumilast and an agent selected from the group consisting of a) an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate, b) diethylene glycol monoethyl ether, c) isopropyl palmitate and combinations thereof.

 




US16/426,492
2018-06-04
2019-05-30
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time 
     
Pending

US20190365642A1
            (en)
        

Priority Applications (1)



Application Number
Priority Date
Filing Date
Title





US16/426,492

US20190365642A1
                          (en)
                      
2018-06-04
2019-05-30
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time 
     



Applications Claiming Priority (3)



Application Number
Priority Date
Filing Date
Title





US201862680203P
2018-06-04
2018-06-04



US201862742644P
2018-10-08
2018-10-08



US16/426,492

US20190365642A1
                          (en)
                      
2018-06-04
2019-05-30
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time 
     



Publications (1)



Publication Number
Publication Date





US20190365642A1
true
US20190365642A1
                       (en)
                   

2019-12-05





Family
ID=68393054
Family Applications (1)



Application Number
Title
Priority Date
Filing Date





US16/426,492
Pending

US20190365642A1
                          (en)
                      

2018-06-04
2019-05-30
Method and Formulation for Improving Roflumilast Skin Penetration Lag Time 
     



Country Status (10)



Country
Link





US
                (1)
              



US20190365642A1
                  (en)
              



EP
                (1)
              
            


EP3801461A2
                  (en)
              



JP
                (1)
              
            


JP2021527037A
                  (en)
              



KR
                (1)
              
            


KR20210044191A
                  (en)
              



CN
                (1)
              
            


CN112384199A
                  (en)
              



AU
                (1)
              
            


AU2019281888A1
                  (en)
              



BR
                (1)
              
            


BR112020024768A8
                  (en)
              



CA
                (1)
              
            


CA3102689A1
                  (en)
              



IL
                (1)
              
            


IL279158A
                  (en)
              



WO
                (1)
              
            


WO2019236374A2
                  (en)
              




Cited By (4)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






WO2021155173A1
              (en)
            
*

2020-01-31
2021-08-05
Arcutis Biotherapeutics, Inc.
Topical roflumilast formulation having improved delivery and plasma half-life 
       



US11129818B2
              (en)
            

2017-06-07
2021-09-28
Arcutis Biotherapeutics, Inc.
Topical roflumilast formulation having improved delivery and plasma half life 
       



WO2021226370A1
              (en)
            
*

2020-05-07
2021-11-11
Arcutis Biotherapeutics, Inc.
Treatment of skin conditions using high krafft temperature anionic surfactants 
       



WO2022169615A1
              (en)
            
*

2021-02-05
2022-08-11
Arcutis Biotherapeutics, Inc.
Roflumilast formulations with an improved pharmacokinetic profile 
       



Family Cites Families (3)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






HU220041B
              (en)
            

1993-07-02
2001-10-28
Byk Gulden Lomberg Chemische Fabrik Gmbh.
Fluoralkoxy substituted benzamide derivatives, process for producing them and pharmaceutical compositions containing them 
       



US9895359B1
              (en)
            
*

2017-06-07
2018-02-20
Arcutis, Inc.
Inhibition of crystal growth of roflumilast 
       



US11534493B2
              (en)
            
*

2017-09-22
2022-12-27
Arcutis Biotherapeutics, Inc.
Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents 
       





2019


2019-05-30
EP
EP19795698.0A
patent/EP3801461A2/en
active
Pending


2019-05-30
AU
AU2019281888A
patent/AU2019281888A1/en
active
Pending


2019-05-30
CN
CN201980046472.1A
patent/CN112384199A/en
active
Pending


2019-05-30
JP
JP2020567541A
patent/JP2021527037A/en
active
Pending


2019-05-30
KR
KR1020207038120A
patent/KR20210044191A/en
unknown



2019-05-30
CA
CA3102689A
patent/CA3102689A1/en
active
Pending


2019-05-30
BR
BR112020024768A
patent/BR112020024768A8/en
unknown



2019-05-30
US
US16/426,492
patent/US20190365642A1/en
active
Pending



2019-05-30
WO
PCT/US2019/034640
patent/WO2019236374A2/en
unknown





2020


2020-12-02
IL
IL279158A
patent/IL279158A/en
unknown






Cited By (4)

* Cited by examiner, â  Cited by third party


Publication number
Priority date
Publication date
Assignee
Title






US11129818B2
            (en)
          

2017-06-07
2021-09-28
Arcutis Biotherapeutics, Inc.
Topical roflumilast formulation having improved delivery and plasma half life 
       



WO2021155173A1
            (en)
          
*

2020-01-31
2021-08-05
Arcutis Biotherapeutics, Inc.
Topical roflumilast formulation having improved delivery and plasma half-life 
       



WO2021226370A1
            (en)
          
*

2020-05-07
2021-11-11
Arcutis Biotherapeutics, Inc.
Treatment of skin conditions using high krafft temperature anionic surfactants 
       



WO2022169615A1
            (en)
          
*

2021-02-05
2022-08-11
Arcutis Biotherapeutics, Inc.
Roflumilast formulations with an improved pharmacokinetic profile 
       




Also Published As



Publication number
Publication date






CA3102689A1
              (en)
            

2019-05-30



CN112384199A
              (en)
            

2021-02-19



AU2019281888A1
              (en)
            

2021-01-14



KR20210044191A
              (en)
            

2021-04-22



BR112020024768A2
              (en)
            

2021-03-30



WO2019236374A3
              (en)
            

2020-01-16



EP3801461A2
              (en)
            

2021-04-14



JP2021527037A
              (en)
            

2021-10-11



BR112020024768A8
              (en)
            

2022-12-13



WO2019236374A2
              (en)
            

2019-12-12



IL279158A
              (en)
            

2021-01-31





Similar Documents



Publication
Publication Date
Title







US11612573B2
                (en)
              


2023-03-28

Topical pharmaceutical compositions 
       




US20190365642A1
                (en)
              


2019-12-05

Method and Formulation for Improving Roflumilast Skin Penetration Lag Time 
     




US20210275509A1
                (en)
              


2021-09-09

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors 
       




US20230091358A1
                (en)
              


2023-03-23

Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents 
     




US11617724B2
                (en)
              


2023-04-04

Topical pharmaceutical compositions 
       




US20210386719A1
                (en)
              


2021-12-16

Topical roflumilast formulation having improved delivery and plasma half life 
     




US20210161870A1
                (en)
              


2021-06-03

Roflumilast formulations with an improved pharmacokinetic profile 
     




US20220211730A1
                (en)
              


2022-07-07

Treatment of skin conditions using high krafft temperature anionic surfactants 
       




WO2022169615A1
                (en)
              


2022-08-11

Roflumilast formulations with an improved pharmacokinetic profile 
       




CA3166300A1
                (en)
              


2021-08-05

Topical roflumilast formulation having improved delivery and plasma half-life 
     




WO2022109626A1
                (en)
              


2022-05-27

Gel, ointment, and foam formulations of tapinarof and methods of use 
       





Legal Events



Date
Code
Title
Description




2019-08-13
STPP
Information on status: patent application and granting procedure in general


Free format text:
              DOCKETED NEW CASE - READY FOR EXAMINATION




2020-12-22
STPP
Information on status: patent application and granting procedure in general


Free format text:
              NON FINAL ACTION MAILED




2021-02-02
STPP
Information on status: patent application and granting procedure in general


Free format text:
              NON FINAL ACTION MAILED




2021-08-05
STPP
Information on status: patent application and granting procedure in general


Free format text:
              RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER




2021-10-01
STCB
Information on status: application discontinuation


Free format text:
              FINAL REJECTION MAILED




2021-12-22
AS
Assignment


Owner name:
              SLR INVESTMENT CORP., AS AGENT, NEW YORK


Free format text:
              SECURITY INTEREST;ASSIGNOR:ARCUTIS BIOTHERAPEUTICS, INC.;REEL/FRAME:058463/0187


Effective date:
              20211222




2022-04-02
STPP
Information on status: patent application and granting procedure in general


Free format text:
              AMENDMENT AFTER NOTICE OF APPEAL




2022-04-30
STCV
Information on status: appeal procedure


Free format text:
              NOTICE OF APPEAL FILED




2022-05-17
STPP
Information on status: patent application and granting procedure in general


Free format text:
              DOCKETED NEW CASE - READY FOR EXAMINATION




2022-09-28
STPP
Information on status: patent application and granting procedure in general


Free format text:
              NON FINAL ACTION MAILED














